PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 2565342-4 1989 Conversion to GRH(3-44)-NH2 was blocked by diprotin A, a DPP type IV (DPP IV) competitive inhibitor. diprotin A 43-53 growth hormone releasing hormone Homo sapiens 14-17 2565342-4 1989 Conversion to GRH(3-44)-NH2 was blocked by diprotin A, a DPP type IV (DPP IV) competitive inhibitor. diprotin A 43-53 dipeptidyl peptidase 4 Homo sapiens 57-68 2565342-4 1989 Conversion to GRH(3-44)-NH2 was blocked by diprotin A, a DPP type IV (DPP IV) competitive inhibitor. diprotin A 43-53 dipeptidyl peptidase 4 Homo sapiens 70-76 2430362-11 1986 We conclude that IPI is caused by cytotoxic as well as noncytotoxic HLA A, B, C, DR-specific antibodies. diprotin A 17-20 major histocompatibility complex, class I, A Homo sapiens 68-73 33128316-6 2021 After adjusting for known prognostic variables in our multivariable analysis, the BRAF WT cohort continued to show PFS and OS benefit with ipi/nivo compared to anti-PD-1 monotherapy. diprotin A 139-142 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 82-86 34052607-4 2021 This study aims to investigate the additive effect of IPI and prepregnancy BMI on PIH. diprotin A 54-57 pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included) Homo sapiens 82-85 34052607-9 2021 RESULTS: IPI and prepregnancy BMI were statistically significantly associated with PIH, both independently and in combination, after adjusting for potential confounders. diprotin A 9-12 pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included) Homo sapiens 83-86 34052607-11 2021 Further, short IPI in combination with underweight BMI was found to be inversely associated with PIH (AOR = 0.64, 95% CI = 0.53, 0.78). diprotin A 15-18 pregnancy-induced hypertension (pre-eclampsia, eclampsia, toxemia of pregnancy included) Homo sapiens 97-100 33986803-3 2021 High TUC338 was closely related to advanced Ann Arbor stage, resistance to CHOP-like treatment, and high IPI (International Prognostic Index). diprotin A 105-108 PCBP2 overlapping transcript 1 Homo sapiens 5-11 33893987-8 2021 When patients were divided into low, low-intermediate, high-intermediate and high-risk groups using the V-IPI model based on VEGF and IPI, PFS rates were 94.4, 74.1, 40.6 and 14.8%, respectively. diprotin A 106-109 vascular endothelial growth factor A Homo sapiens 125-129 33556898-12 2021 CONCLUSION: Results of this MAIC demonstrated durable OS and PFS benefits for patients with BRAF-mutant advanced melanoma treated with NIVO+IPI compared with BRAF/MEK inhibitors, with the greatest benefits noted after 12 months. diprotin A 140-143 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 92-96 33216979-7 2021 beta2-microglobulin levels further stratified patients in the MALT-IPI intermediate-risk group in terms of PFS and OS. diprotin A 67-70 beta-2-microglobulin Homo sapiens 0-19 33113003-6 2021 Immune-related GGT elevation was recorded in 17% (PD-1 group) and 38.5% (Ipi + Nivo group). diprotin A 73-76 gamma-glutamyltransferase 1 Homo sapiens 15-18 32972046-6 2021 This pattern or relationship was also retained in a multivariate model fitted to the age-adjusted IPI and relative dose intensity. diprotin A 98-101 renin binding protein Homo sapiens 85-88 33734005-9 2021 High and very-high CLL-IPI risk groups were associated with high CD38-expression (p = .02) and low CD25ABC (p = .0004). diprotin A 23-26 CD38 molecule Homo sapiens 65-69 33416077-4 2021 DPP-IV inhibitors: sitagliptin, vildagliptin and diprotin A, decreased enzyme activity by a maximum of 95-99% (P<0.001). diprotin A 49-59 dipeptidylpeptidase 4 Rattus norvegicus 0-6 31768966-4 2020 CD25 positivity correlated with an advanced stage, higher R-IPI, higher CNS-IPI, the presence of B symptoms, the presence of extranodal involvement >1, and bone involvement. diprotin A 60-63 interleukin 2 receptor subunit alpha Homo sapiens 0-4 32780847-9 2020 Importantly, BCL6 translocations identified non-GCB lymphomas with favorable BN2/C1-like survival independent of IPI and concurrent DPE status. diprotin A 113-116 BCL6 transcription repressor Homo sapiens 13-17 32566677-7 2020 Interestingly, sitagliptin and diprotin A increased the expression of the tight-junction protein claudin-1 which is an important component of a functional barrier formed by iBREC. diprotin A 31-41 claudin 1 Homo sapiens 97-106 32247474-5 2020 The tripeptide IPV exhibited potent DPP-IV inhibitory activity (IC50: 5.61 +- 0.20 microM) comparable to that reported for the known DPP-IV inhibitor IPI (IC50: 3.20 microM). diprotin A 150-153 dipeptidylpeptidase 4 Rattus norvegicus 133-139 31866290-7 2020 The IC50 values of diprotin A against DPP-IV from human, porcine, and bovine sera were 7.83, 8.62, 9.17 muM, respectively. diprotin A 19-29 dipeptidyl peptidase 4 Homo sapiens 38-44 31866290-7 2020 The IC50 values of diprotin A against DPP-IV from human, porcine, and bovine sera were 7.83, 8.62, 9.17 muM, respectively. diprotin A 19-29 latexin Homo sapiens 104-107 31597702-1 2019 The second WW domain (WW2) of the kidney and brain scaffolding protein, KIBRA, has an isoleucine (Ile-81) rather than a second conserved tryptophan and is primarily unstructured. diprotin A 98-101 WW and C2 domain containing 1 Homo sapiens 72-77 32023875-3 2020 DPP-IV inhibition assays were performed, and evaluated IC50 values of diprotin A, quercetin, coumarin, and sitagliptin were found to be 0.653, 4.02, 54.83, and 5.49 nmol/mL, respectively. diprotin A 70-80 dipeptidyl peptidase 4 Homo sapiens 0-6 32954380-6 2020 Diprotin-A pre-treatment improved HHT1 MNC-migration, but had no effect on normal and HHT2 MNCs. diprotin A 0-10 endoglin Homo sapiens 34-38 31570033-9 2021 In women with PCS, IPI < 12 months was associated with greater than two-fold increased risk of uterine rupture (aRR 2.4, CI 1.5-3.8). diprotin A 19-22 arrestin beta 2 Homo sapiens 112-117 31222719-13 2019 CNS-IPI is valid in elderly R-CHOP-treated DLBCL patients, with the highest risk in those with CNS-IPI 6 and R/A involvement. diprotin A 4-7 DNA damage inducible transcript 3 Homo sapiens 30-34 31607305-6 2019 RESULTS: Compared with patients without P53 expression, the patients with P53 expression had higher LDH level, higher NCCN-IPI scores, lower response to chemotherapy,poorer overall survival(OS) and a higher rate of death(P<0.05). diprotin A 123-126 tumor protein p53 Homo sapiens 74-77 30738449-8 2019 CONCLUSION: The paripheral blood CD14+ monocytes in DLBCL patients highly express the TF and VEGF, which relate with IPI, therapeutic efficacy and survival, thus the TF and VEGF expression levels are of reference significance for evaluating the therapeutic efficacy and prognosis of patients. diprotin A 117-120 CD14 molecule Homo sapiens 33-37 31452749-9 2019 In addition, PD-L1 expression in tumor cells was higher in patients with a low IPI compared with those with a high IPI (P=0.019). diprotin A 79-82 CD274 molecule Homo sapiens 13-18 31452749-9 2019 In addition, PD-L1 expression in tumor cells was higher in patients with a low IPI compared with those with a high IPI (P=0.019). diprotin A 115-118 CD274 molecule Homo sapiens 13-18 31452749-11 2019 The present study demonstrated that PD-L1 expression in tumor cells and in the TME was higher in patients at an early stage of disease compared with those at an advanced stage, and that PD-L1 expression on tumor cells was higher in patients with a low IPI than in those with a high IPI. diprotin A 252-255 CD274 molecule Homo sapiens 186-191 30969102-8 2019 The limits of detection of IPI-ICP-MS for Ni, As, Cd, Sb, and Pb were 0.12, 0.67, 0.027, 0.029, and 0.074 mug L-1, respectively. diprotin A 27-30 immunoglobulin kappa variable 1-16 Homo sapiens 110-113 30738449-6 2019 The expression of TF and VEGF on CD14+ monocytes in DLBCL group showed an increasing tendency along with the increase of IPI index (P<0.01). diprotin A 121-124 coagulation factor III, tissue factor Homo sapiens 18-20 30738449-6 2019 The expression of TF and VEGF on CD14+ monocytes in DLBCL group showed an increasing tendency along with the increase of IPI index (P<0.01). diprotin A 121-124 vascular endothelial growth factor A Homo sapiens 25-29 30738449-6 2019 The expression of TF and VEGF on CD14+ monocytes in DLBCL group showed an increasing tendency along with the increase of IPI index (P<0.01). diprotin A 121-124 CD14 molecule Homo sapiens 33-37 31452749-11 2019 The present study demonstrated that PD-L1 expression in tumor cells and in the TME was higher in patients at an early stage of disease compared with those at an advanced stage, and that PD-L1 expression on tumor cells was higher in patients with a low IPI than in those with a high IPI. diprotin A 282-285 CD274 molecule Homo sapiens 186-191 30365987-4 2019 The peptides were subjected to molecular docking on human DPP-IV where the binding free energies were PFP < YPG < YPL < diprotin A while hydrogen bond interactions were critical in the binding of YPL and YPG. diprotin A 129-139 dipeptidyl peptidase 4 Homo sapiens 58-64 30738449-8 2019 CONCLUSION: The paripheral blood CD14+ monocytes in DLBCL patients highly express the TF and VEGF, which relate with IPI, therapeutic efficacy and survival, thus the TF and VEGF expression levels are of reference significance for evaluating the therapeutic efficacy and prognosis of patients. diprotin A 117-120 coagulation factor III, tissue factor Homo sapiens 86-88 30738449-8 2019 CONCLUSION: The paripheral blood CD14+ monocytes in DLBCL patients highly express the TF and VEGF, which relate with IPI, therapeutic efficacy and survival, thus the TF and VEGF expression levels are of reference significance for evaluating the therapeutic efficacy and prognosis of patients. diprotin A 117-120 vascular endothelial growth factor A Homo sapiens 93-97 29963014-0 2018 In Silico Approaches Applied to the Study of Peptide Analogs of Ile-Pro-Ile in Relation to Their Dipeptidyl Peptidase IV Inhibitory Properties. diprotin A 64-75 dipeptidyl peptidase 4 Homo sapiens 97-120 30599635-4 2018 In the case of measuring water droplets, the measurable size range of the extended IPI enlarges to 10 mum-1 mm, with high-quality fringe patterns favoring the accuracy of measurement. diprotin A 83-86 PWWP domain containing 3A, DNA repair factor Homo sapiens 102-107 30203318-7 2018 Cell-of-origin and MYC/BCL2 expression can further build on CNS-IPI to narrow higher risk patients. diprotin A 64-67 MYC proto-oncogene, bHLH transcription factor Homo sapiens 19-22 30203318-7 2018 Cell-of-origin and MYC/BCL2 expression can further build on CNS-IPI to narrow higher risk patients. diprotin A 64-67 BCL2 apoptosis regulator Homo sapiens 23-27 29963014-4 2018 Ile-Pro-Ile is the most potent DPP-IV inhibitory peptide identified to date. diprotin A 0-11 dipeptidyl peptidase 4 Homo sapiens 31-37 29520565-4 2018 RESULTS: Across all IPIs tested, sag was 62% greater at short than long muscle length, and sag increased as IPI was increased at both muscle lengths. diprotin A 20-23 S-antigen visual arrestin Homo sapiens 33-36 29520565-11 2018 The dependence of sag on IPI is related to IPI-dependent changes in twitch duration and twitch force, and the timing of peak twitch force relative to the peak force of the associated unfused tetanus. diprotin A 25-28 S-antigen visual arrestin Homo sapiens 18-21 29520565-11 2018 The dependence of sag on IPI is related to IPI-dependent changes in twitch duration and twitch force, and the timing of peak twitch force relative to the peak force of the associated unfused tetanus. diprotin A 43-46 S-antigen visual arrestin Homo sapiens 18-21 29380955-7 2018 This effect was abolished by adding the DPP-IV inhibitor, Diprotin A. diprotin A 58-68 dipeptidylpeptidase 4 Rattus norvegicus 40-46 29579950-4 2018 In the presence of diprotin A, an inhibitor of dipeptidyl peptidase IV (DPPIV), the hydrolysis of YFCLT and GLLLPH decreased and their permeabilities increased significantly compared to control group (P<0.05). diprotin A 19-29 dipeptidyl peptidase 4 Homo sapiens 47-70 29579950-4 2018 In the presence of diprotin A, an inhibitor of dipeptidyl peptidase IV (DPPIV), the hydrolysis of YFCLT and GLLLPH decreased and their permeabilities increased significantly compared to control group (P<0.05). diprotin A 19-29 dipeptidyl peptidase 4 Homo sapiens 72-77 29472575-6 2018 Intrathecal application of two DPP4 inhibitors tripeptide isoleucin-prolin-isoleucin (IPI) and the antidiabetic drug vildagliptin resulted in robust opioid-dependent antihyperalgesic effect during inflammation, and milder but significant opioid-independent antihyperalgesic action in the neuropathic model. diprotin A 86-89 dipeptidylpeptidase 4 Rattus norvegicus 31-35 29050963-7 2018 Migration was prominently attenuated in cells exposed to CXCR4 antagonist, AMD3100, yet can be rescued with diprotin A, which prevents the degradation of SDF-1alpha. diprotin A 108-118 C-X-C motif chemokine receptor 4 Homo sapiens 57-62 29253907-6 2017 DipA increased the number of CXCR4+ MNCs residing in the infarcted Eng+/- hearts (Eng+/- 73.17+-12.67 vs. Eng+/- treated 157.00+-11.61, P = 0.0003) and significantly reduced infarct size (Eng+/- 46.60+-9.33% vs. Eng+/- treated 27.02+-3.04%, P = 0.03). diprotin A 0-4 chemokine (C-X-C motif) receptor 4 Mus musculus 29-34 29253907-6 2017 DipA increased the number of CXCR4+ MNCs residing in the infarcted Eng+/- hearts (Eng+/- 73.17+-12.67 vs. Eng+/- treated 157.00+-11.61, P = 0.0003) and significantly reduced infarct size (Eng+/- 46.60+-9.33% vs. Eng+/- treated 27.02+-3.04%, P = 0.03). diprotin A 0-4 endoglin Mus musculus 67-70 29253907-6 2017 DipA increased the number of CXCR4+ MNCs residing in the infarcted Eng+/- hearts (Eng+/- 73.17+-12.67 vs. Eng+/- treated 157.00+-11.61, P = 0.0003) and significantly reduced infarct size (Eng+/- 46.60+-9.33% vs. Eng+/- treated 27.02+-3.04%, P = 0.03). diprotin A 0-4 endoglin Mus musculus 82-85 29253907-6 2017 DipA increased the number of CXCR4+ MNCs residing in the infarcted Eng+/- hearts (Eng+/- 73.17+-12.67 vs. Eng+/- treated 157.00+-11.61, P = 0.0003) and significantly reduced infarct size (Eng+/- 46.60+-9.33% vs. Eng+/- treated 27.02+-3.04%, P = 0.03). diprotin A 0-4 endoglin Mus musculus 82-85 29253907-6 2017 DipA increased the number of CXCR4+ MNCs residing in the infarcted Eng+/- hearts (Eng+/- 73.17+-12.67 vs. Eng+/- treated 157.00+-11.61, P = 0.0003) and significantly reduced infarct size (Eng+/- 46.60+-9.33% vs. Eng+/- treated 27.02+-3.04%, P = 0.03). diprotin A 0-4 endoglin Mus musculus 82-85 29253907-6 2017 DipA increased the number of CXCR4+ MNCs residing in the infarcted Eng+/- hearts (Eng+/- 73.17+-12.67 vs. Eng+/- treated 157.00+-11.61, P = 0.0003) and significantly reduced infarct size (Eng+/- 46.60+-9.33% vs. Eng+/- treated 27.02+-3.04%, P = 0.03). diprotin A 0-4 endoglin Mus musculus 82-85 29253907-7 2017 Echocardiography demonstrated that DipA treatment slightly deteriorated heart function in Eng+/- mice. diprotin A 35-39 endoglin Mus musculus 90-93 29190915-8 2017 The high PB-CD11b+CX3CR1+ monocyte group was significantly associated with high-intermediate and high risk NCCN-IPI group (P = 0.004). diprotin A 112-115 integrin subunit alpha M Homo sapiens 12-17 29308314-5 2018 Furthermore, MM patients receiving IPI who showed extended PFS underwent increased expression of CD80 and CD86 on DC-derived Exo at the end of treatment. diprotin A 35-38 CD80 molecule Homo sapiens 97-101 29308314-5 2018 Furthermore, MM patients receiving IPI who showed extended PFS underwent increased expression of CD80 and CD86 on DC-derived Exo at the end of treatment. diprotin A 35-38 CD86 molecule Homo sapiens 106-110 29308314-6 2018 These results suggest a possible association of both PD-1 and CD28 up-regulation on immune cell-derived Exo in patients with better clinical response to IPI. diprotin A 153-156 MHC class I antigen 1 Sus scrofa 53-57 29308314-6 2018 These results suggest a possible association of both PD-1 and CD28 up-regulation on immune cell-derived Exo in patients with better clinical response to IPI. diprotin A 153-156 CD28 Sus scrofa 62-66 29190915-8 2017 The high PB-CD11b+CX3CR1+ monocyte group was significantly associated with high-intermediate and high risk NCCN-IPI group (P = 0.004). diprotin A 112-115 C-X3-C motif chemokine receptor 1 Homo sapiens 18-24 28756771-9 2017 ABO blood type was found to be superior to both the IPI in discriminating patients with different outcomes in the IPI low-risk group and the KPI in distinguishing between the intermediate-to-low- and high-to-intermediate-risk groups. diprotin A 114-117 ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase Homo sapiens 0-3 28923269-6 2017 Immunocytochemistry of vascular endothelial (VE-) cadherin showed that jagged VE-cadherin staining pattern induced by hypoxia was restored by treatment with Diprotin A. diprotin A 157-167 cadherin 5 Homo sapiens 23-58 28923269-6 2017 Immunocytochemistry of vascular endothelial (VE-) cadherin showed that jagged VE-cadherin staining pattern induced by hypoxia was restored by treatment with Diprotin A. diprotin A 157-167 cadherin 5 Homo sapiens 78-89 28923269-7 2017 The increased level of cleaved beta-catenin in response to hypoxia was significantly attenuated by Diprotin A, suggesting that DPP-4 inhibition protects endothelial adherens junctions from hypoxia. diprotin A 99-109 catenin beta 1 Homo sapiens 31-43 28923269-7 2017 The increased level of cleaved beta-catenin in response to hypoxia was significantly attenuated by Diprotin A, suggesting that DPP-4 inhibition protects endothelial adherens junctions from hypoxia. diprotin A 99-109 dipeptidyl peptidase 4 Homo sapiens 127-132 28923269-8 2017 Subsequently, we found that Diprotin A inhibited hypoxia-induced translocation of NF-kappaB from cytoplasm to nucleus through decreasing TNF-alpha expression level. diprotin A 28-38 nuclear factor kappa B subunit 1 Homo sapiens 82-91 28923269-8 2017 Subsequently, we found that Diprotin A inhibited hypoxia-induced translocation of NF-kappaB from cytoplasm to nucleus through decreasing TNF-alpha expression level. diprotin A 28-38 tumor necrosis factor Homo sapiens 137-146 29081194-7 2017 NCCN-IPI was outstanding to identify the subgroup of low risk patients with PTCL, who may benefit from conventional chemotherapy such as CHOP or CHOP-like regimen. diprotin A 5-8 DNA damage inducible transcript 3 Homo sapiens 137-141 29081194-7 2017 NCCN-IPI was outstanding to identify the subgroup of low risk patients with PTCL, who may benefit from conventional chemotherapy such as CHOP or CHOP-like regimen. diprotin A 5-8 DNA damage inducible transcript 3 Homo sapiens 145-149 28454879-10 2017 Diprotin A was used as a CD26 inhibitor to further investigated the function of CD26 fibroblasts in keloid disease. diprotin A 0-10 dipeptidyl peptidase 4 Homo sapiens 25-29 28726205-0 2017 Dipeptidyl Peptidase 4 Inhibitors Diprotin A and Sitagliptin Administered on Weeks 2-3 of Postnatal Development Modulate Monoamine Metabolism in the Striatum of Adult Rats. diprotin A 34-44 dipeptidylpeptidase 4 Rattus norvegicus 0-22 28726205-1 2017 The levels of monoamines and their metabolites in brain structures of adult (3-month-old) rats with emotional and motivational disorders induced by inhibitors of dipeptidyl peptidase 4 (DPP-4; EC 3.4.14.5) diprotin A and sitagliptin on weeks 2-3 of postnatal development (postnatal days 5-18) were studied by HPLC with electrochemical detection. diprotin A 206-216 dipeptidylpeptidase 4 Rattus norvegicus 162-184 28726205-1 2017 The levels of monoamines and their metabolites in brain structures of adult (3-month-old) rats with emotional and motivational disorders induced by inhibitors of dipeptidyl peptidase 4 (DPP-4; EC 3.4.14.5) diprotin A and sitagliptin on weeks 2-3 of postnatal development (postnatal days 5-18) were studied by HPLC with electrochemical detection. diprotin A 206-216 dipeptidylpeptidase 4 Rattus norvegicus 186-191 28221865-2 2017 Randomized controlled trials of recent US Food and Drug Administration-approved immune checkpoint inhibitors-pembrolizumab (PEM), nivolumab (NIVO), and ipilumumab (IPI)-demonstrate improved patient outcomes, but the optimal treatment sequence in patients with BRAF wild-type metastatic melanoma remains unclear. diprotin A 164-167 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 260-264 28538151-6 2017 The two combinations utilize very different mechanisms to maintain the same IPI distribution, and the mechanistic difference provides a way of identifying IP3R kinetic parameters by observing properties of the IPI. diprotin A 210-213 inositol 1,4,5-trisphosphate receptor type 3 Homo sapiens 155-159 28122441-2 2016 The IPI was calculatedas C-reactive protein x NLR (neutrophil/ lymphocyte ratio)/serum albumin. diprotin A 4-7 C-reactive protein Homo sapiens 25-43 27926587-2 2017 Few data are available on anti-PD1 safety in patients who develop IPI-related severe adverse events (AEs) (grade>=3). diprotin A 66-69 programmed cell death 1 Homo sapiens 31-34 27926587-3 2017 The aim of this study was to compare the anti-PD1 safety and efficacy in patients with previous severe toxicity to IPI versus in those showing moderate and no previous IPI-related AEs. diprotin A 115-118 programmed cell death 1 Homo sapiens 46-49 29860255-1 2017 BACKGROUND: Previous studies have shown the development of emotional and motivational disorders, such as anxiety-depression-like disorders with increased aggression in adolescent and adult Wistar rats, occurs after neonatal exposure to the dipeptidyl peptidase-IV (DPP-IV, EC 3.4.14.5) inhibitors diprotin A and sitagliptin (postnatal days 5-18). diprotin A 297-307 dipeptidylpeptidase 4 Rattus norvegicus 240-263 29860255-1 2017 BACKGROUND: Previous studies have shown the development of emotional and motivational disorders, such as anxiety-depression-like disorders with increased aggression in adolescent and adult Wistar rats, occurs after neonatal exposure to the dipeptidyl peptidase-IV (DPP-IV, EC 3.4.14.5) inhibitors diprotin A and sitagliptin (postnatal days 5-18). diprotin A 297-307 dipeptidylpeptidase 4 Rattus norvegicus 265-271 29860255-2 2017 METHODS: In this study, using real-time PCR, we evaluated changes in the gene expression of serine protease DPP-IV and prolyl endopeptidase (PREP, EC 3.4.21.26; dpp4 and prep genes), monoamine oxidase A (maoA) and B (maoB), and serotonin transporter (SERT; sert) in the brain structures from 3-month-old rats after postnatal action of DPP-IV inhibitors diprotin A and sitagliptin. diprotin A 353-363 kallikrein 1-related peptidase C8 Rattus norvegicus 92-107 29860255-2 2017 METHODS: In this study, using real-time PCR, we evaluated changes in the gene expression of serine protease DPP-IV and prolyl endopeptidase (PREP, EC 3.4.21.26; dpp4 and prep genes), monoamine oxidase A (maoA) and B (maoB), and serotonin transporter (SERT; sert) in the brain structures from 3-month-old rats after postnatal action of DPP-IV inhibitors diprotin A and sitagliptin. diprotin A 353-363 dipeptidylpeptidase 4 Rattus norvegicus 108-114 29860255-2 2017 METHODS: In this study, using real-time PCR, we evaluated changes in the gene expression of serine protease DPP-IV and prolyl endopeptidase (PREP, EC 3.4.21.26; dpp4 and prep genes), monoamine oxidase A (maoA) and B (maoB), and serotonin transporter (SERT; sert) in the brain structures from 3-month-old rats after postnatal action of DPP-IV inhibitors diprotin A and sitagliptin. diprotin A 353-363 prolyl endopeptidase Rattus norvegicus 141-145 27760757-9 2016 The combined molecular and clinical prognostic indices, M-IPI-R and IPI+IHC, have remarkable predictive values in R-CHOP-treated DLBCL. diprotin A 58-61 DNA damage inducible transcript 3 Homo sapiens 116-120 29860255-5 2017 An increase in prep gene expression was found in the striatum of rats with the neonatal action of diprotin A, and a decrease in maoB gene expression was observed in the amygdala. diprotin A 98-108 prolyl endopeptidase Rattus norvegicus 15-19 28122441-2 2016 The IPI was calculatedas C-reactive protein x NLR (neutrophil/ lymphocyte ratio)/serum albumin. diprotin A 4-7 albumin Homo sapiens 87-94 27342497-7 2016 In multivariate analysis, IPI and CD30 were independent prognostic factors for OS (IPI: P=0.000, 95%CI 0.042-0.374, CD30: P=0.044, 95%CI 1.055-60.613), and IPI also was independent prognostic factors for EFS (P=0.000, 95%CI 0.040-0.360). diprotin A 83-86 TNF receptor superfamily member 8 Homo sapiens 34-38 27196819-5 2016 With progression-free survival (PFS) as primary endpoint, the best performing IPI independent model incorporated the LMO2 and HLADQA1 as well as gene interactions for GCSAMxMIB1, GCSAMxCTGF and FOXP1xPDE4B. diprotin A 78-81 LIM domain only 2 Homo sapiens 117-121 27196819-5 2016 With progression-free survival (PFS) as primary endpoint, the best performing IPI independent model incorporated the LMO2 and HLADQA1 as well as gene interactions for GCSAMxMIB1, GCSAMxCTGF and FOXP1xPDE4B. diprotin A 78-81 major histocompatibility complex, class II, DQ alpha 1 Homo sapiens 126-133 27196819-7 2016 However, a simpler, IPI independent model incorporated LMO2 and BCL2 and assigned 33% of the patients with a 3-year PFS of 35% vs. 82% for low risk group (P < 0 001). diprotin A 20-23 LIM domain only 2 Homo sapiens 55-59 27196819-7 2016 However, a simpler, IPI independent model incorporated LMO2 and BCL2 and assigned 33% of the patients with a 3-year PFS of 35% vs. 82% for low risk group (P < 0 001). diprotin A 20-23 BCL2 apoptosis regulator Homo sapiens 64-68 27381080-4 2016 DPP4-inhibitor (diprotin A or sitagliptin) increased the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupted endothelial cell-to-cell junctions, which were attenuated by CXCR4 (receptor of SDF-1alpha)-blocker or Src-inhibitor. diprotin A 16-26 dipeptidyl peptidase 4 Homo sapiens 0-4 27381080-4 2016 DPP4-inhibitor (diprotin A or sitagliptin) increased the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupted endothelial cell-to-cell junctions, which were attenuated by CXCR4 (receptor of SDF-1alpha)-blocker or Src-inhibitor. diprotin A 16-26 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 76-79 27381080-4 2016 DPP4-inhibitor (diprotin A or sitagliptin) increased the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupted endothelial cell-to-cell junctions, which were attenuated by CXCR4 (receptor of SDF-1alpha)-blocker or Src-inhibitor. diprotin A 16-26 cadherin 5 Homo sapiens 84-113 27381080-4 2016 DPP4-inhibitor (diprotin A or sitagliptin) increased the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupted endothelial cell-to-cell junctions, which were attenuated by CXCR4 (receptor of SDF-1alpha)-blocker or Src-inhibitor. diprotin A 16-26 cadherin 5 Homo sapiens 115-126 27381080-4 2016 DPP4-inhibitor (diprotin A or sitagliptin) increased the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupted endothelial cell-to-cell junctions, which were attenuated by CXCR4 (receptor of SDF-1alpha)-blocker or Src-inhibitor. diprotin A 16-26 C-X-C motif chemokine receptor 4 Homo sapiens 230-235 27381080-4 2016 DPP4-inhibitor (diprotin A or sitagliptin) increased the phosphorylation of Src and vascular endothelial-cadherin (VE-cadherin) in human endothelial cells and disrupted endothelial cell-to-cell junctions, which were attenuated by CXCR4 (receptor of SDF-1alpha)-blocker or Src-inhibitor. diprotin A 16-26 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 272-275 27687552-10 2016 The IPI model was implemented using emerging web technologies (i.e. HTML5, CSS3, AJAX, PHP and MySQL). diprotin A 4-7 chondroitin sulfate synthase 3 Homo sapiens 75-79 29244917-0 2016 Omega-3 polyunsaturated fatty acids when administered to lactating rats modify the development of experimental anxiety-depressive state in the rat pups exposed to the dipeptidyl peptidase-IV inhibitor diprotin A on the second - third weeks after the birth. diprotin A 201-211 dipeptidylpeptidase 4 Rattus norvegicus 167-190 29244917-9 2016 Results: Omega-3 PUFAs when administered to the lactating females, prevented the development of depressive-like behavior in adolescent rats neonatally exposed to DPP-IV inhibitor diprotin A, and contributed to the formation of antidepressive phenotype in control rats. diprotin A 179-189 dipeptidylpeptidase 4 Rattus norvegicus 162-168 27342497-7 2016 In multivariate analysis, IPI and CD30 were independent prognostic factors for OS (IPI: P=0.000, 95%CI 0.042-0.374, CD30: P=0.044, 95%CI 1.055-60.613), and IPI also was independent prognostic factors for EFS (P=0.000, 95%CI 0.040-0.360). diprotin A 83-86 TNF receptor superfamily member 8 Homo sapiens 34-38 30695419-1 2016 The inhibitors of proline specific peptidase dipeptidyl peptidase-IV (DPP-IV, CD 26; EC 3.4.14.5) diprotin A (2 mg/kg) and sitagliptin (4 mg/kg) upon daily systemic exposure in rat pups on postnatal days 1-7 induced emotional and motivational disorders in one- and two-month-old rats. diprotin A 98-108 dipeptidylpeptidase 4 Rattus norvegicus 70-76 26950200-6 2016 In contrast, exposure to BPA 5 mg/kg d for 15 days resulted in a premature reduction in GnRH IPI and a trend toward early vaginal opening. diprotin A 93-96 gonadotropin releasing hormone 1 Rattus norvegicus 88-92 30695419-9 2016 The results of the study show that diprotin A compared with sitagliptin negatively affects emotional and motivational behavior in adolescent and adult rats by increased number of indices increasing depression, anxiety, and aggression, while the main result of sitagliptin is increased depression when the animals were treated with the DPP-IV inhibitors in the first postnatal week. diprotin A 35-45 dipeptidylpeptidase 4 Rattus norvegicus 335-341 27044827-7 2016 Moreover, we illustrated that HULC was closely related to DLBCL characteristics, such as Ann Arbor stages, B symptoms, CHOP-like treatment, rituximab and IPI. diprotin A 154-157 hepatocellular carcinoma up-regulated long non-coding RNA Homo sapiens 30-34 26796267-6 2016 The higher expression of LUNAR1 was significantly correlated with stage, rituximab and IPI. diprotin A 87-90 leukemia-associated non-coding IGF1R activator RNA 1 Homo sapiens 25-31 26424560-0 2016 MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. diprotin A 57-60 BCL2 apoptosis regulator Homo sapiens 8-13 26424560-0 2016 MYC and BCL-2 adjusted-International Prognostic Index (A-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. diprotin A 57-60 DNA damage inducible transcript 3 Homo sapiens 180-184 26424560-7 2016 Compared with the IPI, the MYC and BCL-2 adjusted-IPI (A-IPI) better discriminated patients in the high-risk subgroup (4-year overall survival [OS]: 33.3%) than did the IPI (4 year OS: 48.0%). diprotin A 50-53 BCL2 apoptosis regulator Homo sapiens 35-40 26424560-7 2016 Compared with the IPI, the MYC and BCL-2 adjusted-IPI (A-IPI) better discriminated patients in the high-risk subgroup (4-year overall survival [OS]: 33.3%) than did the IPI (4 year OS: 48.0%). diprotin A 50-53 BCL2 apoptosis regulator Homo sapiens 35-40 26424560-7 2016 Compared with the IPI, the MYC and BCL-2 adjusted-IPI (A-IPI) better discriminated patients in the high-risk subgroup (4-year overall survival [OS]: 33.3%) than did the IPI (4 year OS: 48.0%). diprotin A 50-53 BCL2 apoptosis regulator Homo sapiens 35-40 26424560-8 2016 In the era of R-CHOP treatment, MYC and BCL-2 adjusted-IPI is more powerful than the IPI for helping guide treatment planning and interpretation of clinical trials. diprotin A 55-58 DNA damage inducible transcript 3 Homo sapiens 16-20 26424560-8 2016 In the era of R-CHOP treatment, MYC and BCL-2 adjusted-IPI is more powerful than the IPI for helping guide treatment planning and interpretation of clinical trials. diprotin A 55-58 BCL2 apoptosis regulator Homo sapiens 40-45 26878872-6 2016 The prognostic impact in germinal-center-B-cell-like DLBCL was not apparent, which was likely due to the association of p63 expression with high-risk IPI, and potential presence of Np63 isoform in TP63 rearranged patients (a mere speculation). diprotin A 150-153 tumor protein p63 Homo sapiens 120-123 25974110-7 2015 The expression of CD30 implied poor outcome in DLBCL patients treated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest. diprotin A 152-155 TNF receptor superfamily member 8 Homo sapiens 18-22 26656519-6 2015 Anemia and high C-reactive protein levels retain their power in multivariate testing even in the era of the NCCN-IPI. diprotin A 113-116 C-reactive protein Homo sapiens 16-34 26361646-5 2015 RESULTS: Pretreatment anemia, elevated pretreatment CRP levels, and higher risk NCCN-IPI groups were significantly associated with reduced PFS and OS (P = .001 and P = .003 for pretreatment anemia, P = .035 and P = .029 for elevated CRP, and P < .001 and P < .001 for higher risk NCCN-IPI groups). diprotin A 85-88 C-reactive protein Homo sapiens 233-236 26035406-7 2015 CONCLUSIONS: The NCCN-IPI retains its prognostic value in diffuse large B-cell lymphoma patients with F-fluoro-2-deoxy-d-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. diprotin A 22-25 DNA damage inducible transcript 3 Homo sapiens 201-205 25899771-6 2015 CONCLUSIONS: Our study has demonstrated that HCV infection status and low serum albumin level add important prognostic values to the newly proposed NCCN-IPI model for patients with DLBCL. diprotin A 153-156 albumin Homo sapiens 80-87 26586460-4 2016 In multivariate analysis, high expression of Bcl-2 was a significant independent prognostic factor of poor PFS (P = 0.026) and OS (P = 0.007) along with high IPI. diprotin A 158-161 BCL2 apoptosis regulator Homo sapiens 45-50 25974110-7 2015 The expression of CD30 implied poor outcome in DLBCL patients treated with either CHOP or R-CHOP, especially those with the high intermediate/high-risk IPI, possibly indicating that anti-CD30 monoclonal antibody could be of clinical interest. diprotin A 152-155 TNF receptor superfamily member 8 Homo sapiens 187-191 25898242-3 2015 IPI activation during nicotine withdrawal was mediated by increased corticotropin releasing factor (CRF) receptor-1 expression and signalling, which modulated glutamatergic input from the medial habenula (MHb). diprotin A 0-3 corticotropin releasing hormone Mus musculus 68-98 24809328-0 2014 Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A. diprotin A 125-135 dipeptidyl peptidase 4 Homo sapiens 68-73 25894775-2 2015 In intact animals, diprotin A increased cellularity of the thymus and spleen, number of CD4+, CD8+, and CD4+8+ thymocytes and CD3+ splenocytes and reduced cellularity of lymph nodes and the number of antibody-forming cells in the spleen. diprotin A 19-29 CD8a molecule Homo sapiens 94-97 25894775-2 2015 In intact animals, diprotin A increased cellularity of the thymus and spleen, number of CD4+, CD8+, and CD4+8+ thymocytes and CD3+ splenocytes and reduced cellularity of lymph nodes and the number of antibody-forming cells in the spleen. diprotin A 19-29 CD4 molecule Homo sapiens 104-107 24913511-5 2015 Multivariate analysis identified serum B2M as an independent prognostic factor in PFS (hazard ratio [HR] = 3.5, 95% confidence interval [CI]: 1.2-10.0; p = 0.02) and OS (HR = 26.9, 95% CI: 2.7-269.7; p = 0.005), after adjustment for IPI and treatment modalities. diprotin A 233-236 beta-2-microglobulin Homo sapiens 39-42 25894775-0 2015 Effect of Diprotin A, an Inhibitor of Dipeptidyl Peptidase IV, on Immunological Parameters of Lymphocytes in Intact Animals and Animals with Experimental Autoimmune Process. diprotin A 10-20 dipeptidyl peptidase 4 Homo sapiens 38-61 25894775-1 2015 We found the peculiarities of the effects of dipeptidyl peptidase IV inhibitor diprotin A on immunological parameters of lymphocytes in lymphoid organs in intact animals and in animals with experimental autoimmune process. diprotin A 79-89 dipeptidyl peptidase 4 Homo sapiens 45-68 25894775-2 2015 In intact animals, diprotin A increased cellularity of the thymus and spleen, number of CD4+, CD8+, and CD4+8+ thymocytes and CD3+ splenocytes and reduced cellularity of lymph nodes and the number of antibody-forming cells in the spleen. diprotin A 19-29 CD4 molecule Homo sapiens 88-91 25704881-5 2015 Moreover, CXCR4+ was an independent factor predicting poorer progression-free survival in germinal-center B-cell-like (GCB)-DLBCL, but not in ABC-DLBCL; and in patients with an IPI of <=2, but not in those with an IPI>2. diprotin A 177-180 C-X-C motif chemokine receptor 4 Homo sapiens 10-15 24874478-0 2014 C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. diprotin A 109-112 C-reactive protein Homo sapiens 0-18 24805855-8 2014 Twenty-seven cases (45%) with the TNF-alpha-positive and TNFR1-positive subtype of DLBCL, NOS had a poorer prognosis for OS and progression-free survival compared with the 33 cases (55%) with the remaining subtypes, and the TNF-alpha-positive and TNFR1-positive subtype of DLBCL, NOS was also shown to be independent of the IPI. diprotin A 324-327 tumor necrosis factor Homo sapiens 34-43 24793774-8 2014 Two of the potent DPP-IV inhibitors, Ile-Pro-Ile and Trp-Pro (IC50 values of 3.5 and 44.2muM, respectively), were predicted to be gastrointestinally/intestinally stable. diprotin A 37-48 dipeptidyl peptidase 4 Homo sapiens 18-24 24705588-9 2014 We propose that decreased activity of PC1/3 rather than PC2 in pancreatic beta-cells is involved in the impaired proinsulin processing, resulting in elevated IPI levels in T2D patients. diprotin A 158-161 proprotein convertase subtilisin/kexin type 1 Homo sapiens 38-41 24578014-11 2014 CONCLUSIONS: The achievement of a CR with front-line therapy is associated with a prolonged PFS and OS in patients with myc-positive NHL, even after adjusting for type of initial therapy, histology, age, IPI, or the presence of a concurrent BCL2 translocation. diprotin A 204-207 MYC proto-oncogene, bHLH transcription factor Homo sapiens 120-123 24408020-9 2014 In addition, CXCR4 agonist (diprotin A) treatment of ovarian CICs weakened the effects of CDDP and enhanced SDF-1-CXCR4 axis expression in ovarian CICs. diprotin A 28-38 C-X-C motif chemokine receptor 4 Homo sapiens 13-18 24408020-9 2014 In addition, CXCR4 agonist (diprotin A) treatment of ovarian CICs weakened the effects of CDDP and enhanced SDF-1-CXCR4 axis expression in ovarian CICs. diprotin A 28-38 C-X-C motif chemokine ligand 12 Homo sapiens 108-113 24408020-9 2014 In addition, CXCR4 agonist (diprotin A) treatment of ovarian CICs weakened the effects of CDDP and enhanced SDF-1-CXCR4 axis expression in ovarian CICs. diprotin A 28-38 C-X-C motif chemokine receptor 4 Homo sapiens 114-119 24145654-9 2014 The addition of TNF-alpha expression to the IPI may significantly improve the predictive prognostic value. diprotin A 44-47 tumor necrosis factor Homo sapiens 16-25 24659264-8 2014 Kaplan-Meier analysis showed that higher expression level of miR-23a was significantly associated with a poor overall survival (OS) in DLBCL patients (log-rank test, P = 0.029), and multivariable Cox regression revealed the expression of miR-23a (adjusted P = 0.034) and IPI (adjusted P = 0.021) was independently associated with OS. diprotin A 271-274 microRNA 23a Homo sapiens 61-68 24659264-8 2014 Kaplan-Meier analysis showed that higher expression level of miR-23a was significantly associated with a poor overall survival (OS) in DLBCL patients (log-rank test, P = 0.029), and multivariable Cox regression revealed the expression of miR-23a (adjusted P = 0.034) and IPI (adjusted P = 0.021) was independently associated with OS. diprotin A 271-274 microRNA 23a Homo sapiens 238-245 23532628-6 2014 Carriers of TGF-beta Pro10 allele more frequently had an advanced clinical stage III/IV (OR 4.65, 95 % CI 1.33-16.19; p = 0.016) and intermediate-high/high IPI score (OR 5.37, 95 % CI 1.45-20.0; p = 0.012). diprotin A 156-159 transforming growth factor beta 1 Homo sapiens 12-20 24705588-9 2014 We propose that decreased activity of PC1/3 rather than PC2 in pancreatic beta-cells is involved in the impaired proinsulin processing, resulting in elevated IPI levels in T2D patients. diprotin A 158-161 insulin Homo sapiens 113-123 22832533-7 2012 NPY overflow experienced a slight increase following field stimulation and significantly increased (P < 0.05) over control conditions in the presence of a DPPIV inhibitor (diprotin A). diprotin A 175-185 neuropeptide Y Rattus norvegicus 0-3 25494872-9 2014 Estrogen-induced knockdown of CG15630 in adults reduced the IPI. diprotin A 60-63 factor of interpulse interval Drosophila melanogaster 30-37 25494872-12 2014 Other genes (Sps2, CG34460), whose CNS-specific knockdown resulted in IPI reduction, are also worthy of detailed examination. diprotin A 70-73 Selenophosphate synthetase 2 Drosophila melanogaster 13-17 25494872-12 2014 Other genes (Sps2, CG34460), whose CNS-specific knockdown resulted in IPI reduction, are also worthy of detailed examination. diprotin A 70-73 uncharacterized protein Drosophila melanogaster 19-26 23775435-7 2013 We were able to reproduce data suggesting an IPI- and response to therapy independent, negative prognostic impact of CCNE in CHOP-treated DLBCL patients: CCNE-positive cases had a median survival of 16 months compared with 57 months in negative ones (p=0.012). diprotin A 45-48 cyclin E1 Homo sapiens 117-121 23775435-7 2013 We were able to reproduce data suggesting an IPI- and response to therapy independent, negative prognostic impact of CCNE in CHOP-treated DLBCL patients: CCNE-positive cases had a median survival of 16 months compared with 57 months in negative ones (p=0.012). diprotin A 45-48 DNA damage inducible transcript 3 Homo sapiens 125-129 23775435-7 2013 We were able to reproduce data suggesting an IPI- and response to therapy independent, negative prognostic impact of CCNE in CHOP-treated DLBCL patients: CCNE-positive cases had a median survival of 16 months compared with 57 months in negative ones (p=0.012). diprotin A 45-48 cyclin E1 Homo sapiens 154-158 24167744-4 2013 In total patient"s group cystatin C levels correlated with beta 2M and IPI. diprotin A 71-74 cystatin C Homo sapiens 25-35 23984080-8 2013 To the best of our knowledge, this is the first study which investigated the impact of R-CHOP in the context of CoO and IPI in a relatively young cohort. diprotin A 120-123 DNA damage inducible transcript 3 Homo sapiens 89-93 23576557-10 2013 Cetuximab plus IPI-926 forces tumor cells into an EGFR-dependent state, delaying or completely blocking tumor recurrence. diprotin A 15-18 epidermal growth factor receptor Homo sapiens 50-54 23335369-8 2013 A combined immunohistochemical or FISH/immunohistochemical score predicts outcome in DLBCL patients independent of the IPI and identifies a subset of 15% of patients with dismal prognosis in the high-risk IPI group following treatment with R-CHOP. diprotin A 205-208 DNA damage inducible transcript 3 Homo sapiens 242-246 23998120-7 2013 The VEGF 936T variant was also more frequent among patients with IPI 4 than in controls (OR = 3.37, P = 0.029). diprotin A 65-68 vascular endothelial growth factor A Homo sapiens 4-8 23324230-9 2012 In addition, there were more CD21(+) lymphoma patients with IPI 0-2 (68.0%, 17/25) than CD21(-)lymphoma patients (41.8%, 23/55). diprotin A 60-63 complement C3d receptor 2 Homo sapiens 29-33 23324230-15 2012 CONCLUSIONS: The expression of CD21 is associated with young age at onset, early clinical stage, small number of involvement and low IPI index. diprotin A 133-136 complement C3d receptor 2 Homo sapiens 31-35 22846168-6 2012 We observed that although CB had greater CD26 expression than bone marrow or mobilized peripheral blood, treatment with a CD26 inhibitor (Diprotin A) resulted in increased responsiveness to stromal cell-derived factor-1 for all three mononuclear cell sources tested. diprotin A 138-148 dipeptidyl peptidase 4 Homo sapiens 122-126 22846168-6 2012 We observed that although CB had greater CD26 expression than bone marrow or mobilized peripheral blood, treatment with a CD26 inhibitor (Diprotin A) resulted in increased responsiveness to stromal cell-derived factor-1 for all three mononuclear cell sources tested. diprotin A 138-148 C-X-C motif chemokine ligand 12 Homo sapiens 190-219 22832533-7 2012 NPY overflow experienced a slight increase following field stimulation and significantly increased (P < 0.05) over control conditions in the presence of a DPPIV inhibitor (diprotin A). diprotin A 175-185 dipeptidylpeptidase 4 Rattus norvegicus 158-163 23181121-7 2012 Although the IPI remained predictive for the CHOP-like group, it failed to distinguish between the various prognostic categories in the R-CHOP-like group. diprotin A 13-16 DNA damage inducible transcript 3 Homo sapiens 45-49 23181121-8 2012 Notably, redistribution of the IPI factors into R-IPI factors identified three discrete prognostic groups with significantly different outcomes in both the CHOP-like and R-CHOP-like groups. diprotin A 31-34 DNA damage inducible transcript 3 Homo sapiens 156-160 23181121-8 2012 Notably, redistribution of the IPI factors into R-IPI factors identified three discrete prognostic groups with significantly different outcomes in both the CHOP-like and R-CHOP-like groups. diprotin A 31-34 DNA damage inducible transcript 3 Homo sapiens 172-176 22440390-8 2012 The IPI and the PIT scores in general predict survival in patients with ALK+ ALCL. diprotin A 4-7 ALK receptor tyrosine kinase Homo sapiens 72-75 21902578-6 2012 IL-6 levels remained a significant outcome predictor also including IPI as a covariate (p = 0.006 for progression-free survival). diprotin A 68-71 interleukin 6 Homo sapiens 0-4 22160255-6 2012 But in the CHOP group, IPI still distinguished four risk groups. diprotin A 23-26 DNA damage inducible transcript 3 Homo sapiens 11-15 22167343-8 2012 Interestingly, inhibition of DPP4 activity with diprotin A also enhanced the amount of Tissue Factor encountered and induced the adherence of platelets under flow conditions. diprotin A 48-58 dipeptidyl peptidase 4 Homo sapiens 29-33 22800477-8 2012 In the condition of different GCB type, different therapy and low IPI (0 ~ 2), the OS of CD5(+) DLBCL patients was significantly lower than that of CD5(-) patients, while in the condition of high IPI (3 ~ 5), the OS of CD5(+) and CD5(-) DLBCL patient had no obvious difference. diprotin A 66-69 CD5 molecule Homo sapiens 89-92 22800477-9 2012 CONCLUSIONS: CD5 expression is an adverse prognostic factor in DLBCL and it has more prognostic value in the condition of low IPI (0 ~ 2). diprotin A 126-129 CD5 molecule Homo sapiens 13-16 22340947-7 2012 However, diprotin A, a positive modulator of CXCR4-SDF-1 binding, significantly enhanced engraftment and stimulated sustained proliferation of donor cells in vivo. diprotin A 9-19 C-X-C motif chemokine receptor 4 Homo sapiens 45-50 22340947-7 2012 However, diprotin A, a positive modulator of CXCR4-SDF-1 binding, significantly enhanced engraftment and stimulated sustained proliferation of donor cells in vivo. diprotin A 9-19 C-X-C motif chemokine ligand 12 Homo sapiens 51-56 22167343-8 2012 Interestingly, inhibition of DPP4 activity with diprotin A also enhanced the amount of Tissue Factor encountered and induced the adherence of platelets under flow conditions. diprotin A 48-58 coagulation factor III, tissue factor Homo sapiens 87-100 21718130-6 2011 The revised IPI better predicted survival than did the standard IPI in patients with DLBCL treated with R-CHOP. diprotin A 12-15 DNA damage inducible transcript 3 Homo sapiens 106-110 21849352-5 2012 Mice were then treated with saline or with granulocyte colony-stimulating factor (G-CSF) plus the dipeptidylpeptidase-IV (DPP-IV) inhibitor Diprotin A (DipA) for 7 days. diprotin A 140-150 dipeptidylpeptidase 4 Mus musculus 98-120 21849352-5 2012 Mice were then treated with saline or with granulocyte colony-stimulating factor (G-CSF) plus the dipeptidylpeptidase-IV (DPP-IV) inhibitor Diprotin A (DipA) for 7 days. diprotin A 140-150 dipeptidylpeptidase 4 Mus musculus 122-128 21849352-5 2012 Mice were then treated with saline or with granulocyte colony-stimulating factor (G-CSF) plus the dipeptidylpeptidase-IV (DPP-IV) inhibitor Diprotin A (DipA) for 7 days. diprotin A 152-156 dipeptidylpeptidase 4 Mus musculus 122-128 21849352-6 2012 Infarct thickness and cardiomyocyte number/infarct/section were significantly improved in MHC-cycD2 mice with G-CSF plus DipA treatment when compared with MHC-cycD2 transgene expression or G-CSF plus DipA treatment alone. diprotin A 200-204 colony stimulating factor 3 (granulocyte) Mus musculus 110-115 22514683-6 2012 The maximal IPi for NPT2a substrates was reduced when CFTR was co-expressed with NPT2a, suggesting a decrease in its expression at the oolemna. diprotin A 12-15 cystic fibrosis transmembrane conductance regulator L homeolog Xenopus laevis 54-58 22514683-8 2012 In NPT2a+CFTR- but not in NPT2a-oocytes, IPi and NPT2a surface expression were increased upon PKA stimulation, whereas stimulation of Exchange Protein directly Activated by cAMP (EPAC) had no effect. diprotin A 41-44 cystic fibrosis transmembrane conductance regulator L homeolog Xenopus laevis 9-13 22514683-9 2012 When NPT2a-oocytes were injected with NEG2, a short amino-acid sequence from the CFTR regulatory domain that regulates PKA-dependent CFTR trafficking to the plasma membrane, IPi values and NPT2a membrane expression were diminished, and could be enhanced by PKA stimulation, thereby mimicking the effects of CFTR co-expression. diprotin A 174-177 cystic fibrosis transmembrane conductance regulator L homeolog Xenopus laevis 81-85 21752744-4 2011 METHODOLOGY/PRINCIPAL FINDINGS: After surgically induced ligation of the LAD, SDF-1/CXCR4 interactions were specifically blocked by the CXCR4 receptor antagonist AMD3100 in G-CSF and Diprotin A treated C57BL/6 mice. diprotin A 183-193 chemokine (C-X-C motif) ligand 12 Mus musculus 78-83 21752744-4 2011 METHODOLOGY/PRINCIPAL FINDINGS: After surgically induced ligation of the LAD, SDF-1/CXCR4 interactions were specifically blocked by the CXCR4 receptor antagonist AMD3100 in G-CSF and Diprotin A treated C57BL/6 mice. diprotin A 183-193 chemokine (C-X-C motif) receptor 4 Mus musculus 84-89 21752744-4 2011 METHODOLOGY/PRINCIPAL FINDINGS: After surgically induced ligation of the LAD, SDF-1/CXCR4 interactions were specifically blocked by the CXCR4 receptor antagonist AMD3100 in G-CSF and Diprotin A treated C57BL/6 mice. diprotin A 183-193 chemokine (C-X-C motif) receptor 4 Mus musculus 136-141 21752744-4 2011 METHODOLOGY/PRINCIPAL FINDINGS: After surgically induced ligation of the LAD, SDF-1/CXCR4 interactions were specifically blocked by the CXCR4 receptor antagonist AMD3100 in G-CSF and Diprotin A treated C57BL/6 mice. diprotin A 183-193 peripheral blood stem cell response to granulocyte colony stimulating factor 1 Mus musculus 173-178 21752744-7 2011 AMD3100 treatment of G-CSF and Diprotin A stimulated mice significantly decreased myocardial homing of circulating stem cells (FACS analysis) and inverted the beneficial effects of (i) cardiac remodeling (histological analyses), (ii) heart function (Millar tip catheterization) and (iii) survival (Kaplan-Meier curves). diprotin A 31-41 acyl-CoA synthetase long-chain family member 1 Mus musculus 127-131 22040968-3 2011 As a results, the multivariate analysis showed that VEGF-C level in non-Hodgkin"s lymphoma patients was low, but high in Hodgkin"s lymphoma patients; VEGFR-2 level was higher in patients > 60 years, while VEGF-D level was lower in patients with IPI > 2. diprotin A 248-251 vascular endothelial growth factor C Homo sapiens 52-58 22040968-3 2011 As a results, the multivariate analysis showed that VEGF-C level in non-Hodgkin"s lymphoma patients was low, but high in Hodgkin"s lymphoma patients; VEGFR-2 level was higher in patients > 60 years, while VEGF-D level was lower in patients with IPI > 2. diprotin A 248-251 kinase insert domain receptor Homo sapiens 150-157 21737509-6 2011 RESULTS: Treatment with IPI-493 resulted in tumor growth stabilization, variable proliferation arrest, induction of apoptosis and necrosis, and downregulation of KIT and its signaling cascade, especially in the GIST-BOE model. diprotin A 24-27 KIT proto-oncogene, receptor tyrosine kinase Homo sapiens 162-165 20153005-5 2011 Dipeptidyl peptidase IV in both areas was distinguished kinetically as insensitive (DI) and sensitive (DS) to diprotin A. diprotin A 110-120 dipeptidylpeptidase 4 Rattus norvegicus 0-23 21385875-8 2011 Protein analysis of Grc3-containing complexes led to the identification of Las1 and components of the IPI complex (Rix1, Ipi1, and Crb3). diprotin A 102-105 polynucleotide 5'-hydroxyl-kinase Saccharomyces cerevisiae S288C 20-24 21385875-10 2011 Our data suggest that Grc3 functions cooperatively with Las1 and the IPI complex in both ribosome biogenesis and heterochromatin assembly. diprotin A 69-72 polynucleotide 5'-hydroxyl-kinase Saccharomyces cerevisiae S288C 22-26 21035853-2 2011 In diffuse large B-cell lymphoma (DLBCL), p16(INK4a) methylation has been associated with advanced disease stage and higher IPI. diprotin A 124-127 cyclin dependent kinase inhibitor 2A Homo sapiens 42-45 21035853-2 2011 In diffuse large B-cell lymphoma (DLBCL), p16(INK4a) methylation has been associated with advanced disease stage and higher IPI. diprotin A 124-127 cyclin dependent kinase inhibitor 2A Homo sapiens 46-51 21439815-8 2011 In receiver operating characteristic (ROC) analyses the accuracy of the IPI to correctly classify patients with favourable or poor survival was improved from fair to good by complementing the IPI with serum angiogenin concentration. diprotin A 72-75 angiogenin Homo sapiens 207-217 21439815-10 2011 CONCLUSIONS: We conclude that elevated serum angiogenin surfaced as an independent predictor for failure in long-term treatment response and for poor overall survival in a series of 204 NHL patients, and might thus also complement the IPI in identifying the patients with particularly aggressive and/or treatment resistant disease. diprotin A 235-238 angiogenin Homo sapiens 45-55 21506127-6 2011 In a multivariate analysis using a Cox proportional hazard model for IPI and NF-kappaB expression, the relative risk was 2.97 for high NF-kappaB expression (95% CI 1.27-6.94; p = 0.0113) and 7.55 for the high-IPI group (95% CI 3.34-18.35; p < 0.0001). diprotin A 69-72 nuclear factor kappa B subunit 1 Homo sapiens 135-144 21258415-2 2011 We show here that the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein, presumed to be the oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC), is associated with Hsp90 in cells and is rapidly degraded upon exposure of cells to IPI-504. diprotin A 312-315 EMAP like 4 Homo sapiens 22-70 21258415-2 2011 We show here that the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein, presumed to be the oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC), is associated with Hsp90 in cells and is rapidly degraded upon exposure of cells to IPI-504. diprotin A 312-315 EMAP like 4 Homo sapiens 72-76 21258415-2 2011 We show here that the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein, presumed to be the oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC), is associated with Hsp90 in cells and is rapidly degraded upon exposure of cells to IPI-504. diprotin A 312-315 ALK receptor tyrosine kinase Homo sapiens 106-109 20153005-9 2011 The existence of DPPIV-like activity with different sensitivities to diprotin A and the identity of insensitive with CD26 were demonstrated for the first time in the central nervous system. diprotin A 69-79 dipeptidylpeptidase 4 Rattus norvegicus 17-22 20385988-11 2010 These results demonstrate that the IPI is still valid in the R-CHOP era. diprotin A 35-38 DNA damage inducible transcript 3 Homo sapiens 63-67 22022585-6 2011 Co-expression network analysis showed that: i) CA3 transcriptomic profiles differ according to the IPI; ii) FS distinctive hubs are mostly linked to glutamatergic signalization while NFS hubs predominantly involve GABAergic pathways and neurotransmission modulation. diprotin A 99-102 carbonic anhydrase 3 Homo sapiens 47-50 20535821-11 2010 In particular, we propose that the palindromic IPI motif of alphaB-crystallin gives rise to two orientations of the C-terminus. diprotin A 47-50 crystallin alpha B Bos taurus 60-77 20685743-9 2010 After adjustment for other independent risk factors in a conditional logistic regression model, IPI was associated with both LRA (matched OR (mOR) 2.8; 95% CI 2.1 to 3.6) and HRA (mOR, 12.3; 95% CI 5.4 to 28.0). diprotin A 96-99 FRY like transcription coactivator Homo sapiens 130-148 20940010-1 2011 We have reported previously that the dipeptidyl peptidase IV inhibitor Ile-Pro-Ile had an antihyperalgesic action in rats when given intrathecally in the carrageenan-induced hyperalgesia, as detected by the Randall-Selitto test. diprotin A 71-82 dipeptidylpeptidase 4 Rattus norvegicus 37-60 20802132-10 2010 On day 28 after cell sheet transplantation, the number of Y(ch+) was increased in the MSC(CXCR4) + VEH group compared with the MSC(Null) + VEH group and further increased in the MSC(CXCR4) + DIP treated group. diprotin A 191-194 C-X-C motif chemokine receptor 4 Rattus norvegicus 182-187 19448608-5 2009 CYBA rs4673 and GSTA1 rs3957357 also predicted outcome in DLBCL subgroups by IPI. diprotin A 77-80 glutathione S-transferase alpha 1 Homo sapiens 16-21 19757311-4 2009 PKC-beta II expression correlated with inferior overall survival (OS) and progression-free survival (PFS) in CHOP-treated patients with low-risk International Prognostic Index (IPI) disease (0-2 adverse factors), but not in the overall patient group unstratified by IPI. diprotin A 177-180 DNA damage inducible transcript 3 Homo sapiens 109-113 19205655-8 2009 IPI is still important in predicting the prognosis in the R-CHOP era in DLBCL; however, obtaining CR after four cycles of R-CHOP and presence of bulky disease should be considered together. diprotin A 0-3 DNA damage inducible transcript 3 Homo sapiens 60-64 19821819-6 2010 VEGFR1 was not predictive of survival on univariate analysis, but it did correlate with better OS on multivariate analysis with VEGF, VEGFR2 and IPI (P = 0.036); in patients with weak VEGFR2, lack of VEGFR1 coexpression was significantly correlated with poor OS independent of IPI (P = 0.01). diprotin A 145-148 fms related receptor tyrosine kinase 1 Homo sapiens 0-6 19821819-6 2010 VEGFR1 was not predictive of survival on univariate analysis, but it did correlate with better OS on multivariate analysis with VEGF, VEGFR2 and IPI (P = 0.036); in patients with weak VEGFR2, lack of VEGFR1 coexpression was significantly correlated with poor OS independent of IPI (P = 0.01). diprotin A 145-148 vascular endothelial growth factor A Homo sapiens 0-4 19821819-6 2010 VEGFR1 was not predictive of survival on univariate analysis, but it did correlate with better OS on multivariate analysis with VEGF, VEGFR2 and IPI (P = 0.036); in patients with weak VEGFR2, lack of VEGFR1 coexpression was significantly correlated with poor OS independent of IPI (P = 0.01). diprotin A 277-280 fms related receptor tyrosine kinase 1 Homo sapiens 0-6 19821819-6 2010 VEGFR1 was not predictive of survival on univariate analysis, but it did correlate with better OS on multivariate analysis with VEGF, VEGFR2 and IPI (P = 0.036); in patients with weak VEGFR2, lack of VEGFR1 coexpression was significantly correlated with poor OS independent of IPI (P = 0.01). diprotin A 277-280 vascular endothelial growth factor A Homo sapiens 0-4 19665574-6 2009 The proteolytic activity was inhibited in a concentration-dependent manner by a specific DPP4 inhibitor, diprotin A, which indicates that the activity is probably due to the presence of DPP4. diprotin A 105-115 dipeptidyl peptidase 4 Alligator mississippiensis 89-93 19665574-6 2009 The proteolytic activity was inhibited in a concentration-dependent manner by a specific DPP4 inhibitor, diprotin A, which indicates that the activity is probably due to the presence of DPP4. diprotin A 105-115 dipeptidyl peptidase 4 Alligator mississippiensis 186-190 19695241-0 2009 Intrathecally injected Ile-Pro-Ile, an inhibitor of membrane ectoenzyme dipeptidyl peptidase IV, is antihyperalgesic in rats by switching the enzyme from hydrolase to synthase functional mode to generate endomorphin 2. diprotin A 23-34 dipeptidylpeptidase 4 Rattus norvegicus 72-95 19695241-1 2009 We have found recently that membrane-bound dipeptidyl peptidase IV (DPP-IV) generated extracellularly immunoreactive endomorphin-2 from Tyr-Pro precursor in a depolarisation-sensitive manner in rat isolated L4,5 dorsal root ganglia when the enzyme was switched to synthase mode by the hydrolase inhibitor Ile-Pro-Ile. diprotin A 305-316 dipeptidylpeptidase 4 Rattus norvegicus 43-66 19695241-1 2009 We have found recently that membrane-bound dipeptidyl peptidase IV (DPP-IV) generated extracellularly immunoreactive endomorphin-2 from Tyr-Pro precursor in a depolarisation-sensitive manner in rat isolated L4,5 dorsal root ganglia when the enzyme was switched to synthase mode by the hydrolase inhibitor Ile-Pro-Ile. diprotin A 305-316 dipeptidylpeptidase 4 Rattus norvegicus 68-74 19540879-6 2009 It is concluded that E2-IR was generated extracellularly by a membrane-bound DPP-IV, which was switched to "synthase" mode by the hydrolase inhibitor Ile-Pro-Ile. diprotin A 150-161 dipeptidylpeptidase 4 Rattus norvegicus 77-83 19540435-0 2009 Enhanced homing and engraftment of fresh but not ex vivo cultured murine marrow cells in submyeloablated hosts following CD26 inhibition by Diprotin A. diprotin A 140-150 dipeptidylpeptidase 4 Mus musculus 121-125 19540435-2 2009 Here, we evaluated homing efficiency as a potential mechanism for this engraftment disparity, and whether CD26 inhibition with the tripeptide Diprotin A (DipA) would enhance engraftment of ex vivo cultured cells in submyeloablated hosts. diprotin A 142-152 dipeptidylpeptidase 4 Mus musculus 106-110 19540435-2 2009 Here, we evaluated homing efficiency as a potential mechanism for this engraftment disparity, and whether CD26 inhibition with the tripeptide Diprotin A (DipA) would enhance engraftment of ex vivo cultured cells in submyeloablated hosts. diprotin A 154-158 dipeptidylpeptidase 4 Mus musculus 106-110 17577773-9 2007 IPI score was similar in both BCL-2 positive and negative cases. diprotin A 0-3 BCL2 apoptosis regulator Homo sapiens 30-35 19406723-10 2009 In subgroup analysis, the effect of CD43 expression was significant in patients treated with rituximab and those with low IPI, whereas it was not reached in patients treated without rituximab. diprotin A 122-125 sialophorin Homo sapiens 36-40 19298719-7 2009 The OS of the GCB group also was longer compared to that of the non-GCB group in low IPI subgroup (p=0.01). diprotin A 85-88 glucosylceramidase beta Homo sapiens 14-17 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 golgi membrane protein 1 Homo sapiens 383-389 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 hemoglobin subunit alpha 1 Homo sapiens 391-395 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 H1.2 linker histone, cluster member Homo sapiens 397-405 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 myristoylated alanine rich protein kinase C substrate Homo sapiens 418-424 18790753-5 2008 In vitro treatment of pancreatic cancer cell lines with IPI-269609 resembled effects observed using cyclopamine (i.e., Gli-responsive reporter knockdown, down-regulation of the Hedgehog target genes Gli1 and Ptch, as well as abrogation of cell migration and colony formation in soft agar). diprotin A 56-59 GLI family zinc finger 1 Homo sapiens 119-122 18790753-5 2008 In vitro treatment of pancreatic cancer cell lines with IPI-269609 resembled effects observed using cyclopamine (i.e., Gli-responsive reporter knockdown, down-regulation of the Hedgehog target genes Gli1 and Ptch, as well as abrogation of cell migration and colony formation in soft agar). diprotin A 56-59 GLI family zinc finger 1 Homo sapiens 199-203 18790753-5 2008 In vitro treatment of pancreatic cancer cell lines with IPI-269609 resembled effects observed using cyclopamine (i.e., Gli-responsive reporter knockdown, down-regulation of the Hedgehog target genes Gli1 and Ptch, as well as abrogation of cell migration and colony formation in soft agar). diprotin A 56-59 patched 1 Homo sapiens 208-212 18231911-7 2008 Regarding International Prognostic Index (IPI), HGF mean serum level at diagnosis was significantly higher for patients with IPI >2 when compared to IPI <or=2. diprotin A 42-45 hepatocyte growth factor Homo sapiens 48-51 18203020-0 2008 The expression of anamorsin in diffuse large B cell lymphoma: possible prognostic biomarker for low IPI patients. diprotin A 100-103 cytokine induced apoptosis inhibitor 1 Homo sapiens 18-27 18203020-5 2008 However, anamorsin expression in DLBCL patients with a low IPI was shown to be an unfavorable biomarker, especially in the patients who received chemotherapy without rituximab. diprotin A 59-62 cytokine induced apoptosis inhibitor 1 Homo sapiens 9-18 19672286-13 2007 MIB-1 could also identify some high-risk patients previously categorized in the IPI lowrisk group. diprotin A 80-83 MIB E3 ubiquitin protein ligase 1 Homo sapiens 0-5 19860734-6 2009 More recently, Infinity Pharmaceuticals initiated a Phase 1 clinical trial with an oral formulation of 17-AG (IPI-493), the major metabolite of 17-AAG and IPI-504. diprotin A 110-113 N-methylpurine DNA glycosylase Homo sapiens 147-150 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 heat shock protein family A (Hsp70) member 1B Homo sapiens 346-352 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 galectin 3 Homo sapiens 354-360 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 calmodulin 1 Homo sapiens 362-367 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 LRAT domain containing 2 Homo sapiens 369-375 18852131-7 2008 Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor growth Identical changes were observed in the expression of the genes coding for these proteins in a subset of proteins including HSPA1B, LGALS3, CALM1, FAM84B, FDPS, GOLPH2, HBA1, HIST1H1C, HLA-B, and MARCKS. diprotin A 192-195 farnesyl diphosphate synthase Homo sapiens 377-381 18515407-6 2008 Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung. diprotin A 27-37 dipeptidylpeptidase 4 Mus musculus 65-69 18515407-6 2008 Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung. diprotin A 27-37 chemokine (C-X-C motif) ligand 12 Mus musculus 133-138 18515407-6 2008 Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung. diprotin A 27-37 chemokine (C-X-C motif) ligand 12 Mus musculus 139-145 18515407-6 2008 Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung. diprotin A 27-37 chemokine (C-X-C motif) receptor 4 Mus musculus 147-152 18086797-7 2008 Similarly, in patients treated with the combination of anthracycline-containing regimens and rituximab, LMO2 protein expression was also significantly correlated with improved OS and PFS (OS, P = .005; PFS, P = .009) and was a significant predictor independent of the IPI in multivariate analysis. diprotin A 268-271 LIM domain only 2 Homo sapiens 104-108 17280591-11 2007 When used alone, SHU 9119 or a CRF-receptor antagonist resulted in increased GnRH IPI at 50 days while they had no effects at 15 days. diprotin A 82-85 gonadotropin releasing hormone 1 Rattus norvegicus 77-81 17492130-5 2007 In order to elucidate the hDPPIV binding mode and substrate specificity, we determined the crystal structure of hDPPIV-diprotin B (Val-Pro-Leu) complex at 2.1 A resolution, and clarified the difference in binding mode between diprotin B and diprotin A (Ile-Pro-Ile) into the active site of hDPPIV. diprotin A 241-251 dipeptidyl peptidase 4 Homo sapiens 26-32 17492130-5 2007 In order to elucidate the hDPPIV binding mode and substrate specificity, we determined the crystal structure of hDPPIV-diprotin B (Val-Pro-Leu) complex at 2.1 A resolution, and clarified the difference in binding mode between diprotin B and diprotin A (Ile-Pro-Ile) into the active site of hDPPIV. diprotin A 241-251 dipeptidyl peptidase 4 Homo sapiens 112-118 17492130-5 2007 In order to elucidate the hDPPIV binding mode and substrate specificity, we determined the crystal structure of hDPPIV-diprotin B (Val-Pro-Leu) complex at 2.1 A resolution, and clarified the difference in binding mode between diprotin B and diprotin A (Ile-Pro-Ile) into the active site of hDPPIV. diprotin A 241-251 dipeptidyl peptidase 4 Homo sapiens 112-118 17492130-5 2007 In order to elucidate the hDPPIV binding mode and substrate specificity, we determined the crystal structure of hDPPIV-diprotin B (Val-Pro-Leu) complex at 2.1 A resolution, and clarified the difference in binding mode between diprotin B and diprotin A (Ile-Pro-Ile) into the active site of hDPPIV. diprotin A 253-264 dipeptidyl peptidase 4 Homo sapiens 26-32 17492130-5 2007 In order to elucidate the hDPPIV binding mode and substrate specificity, we determined the crystal structure of hDPPIV-diprotin B (Val-Pro-Leu) complex at 2.1 A resolution, and clarified the difference in binding mode between diprotin B and diprotin A (Ile-Pro-Ile) into the active site of hDPPIV. diprotin A 253-264 dipeptidyl peptidase 4 Homo sapiens 112-118 17492130-5 2007 In order to elucidate the hDPPIV binding mode and substrate specificity, we determined the crystal structure of hDPPIV-diprotin B (Val-Pro-Leu) complex at 2.1 A resolution, and clarified the difference in binding mode between diprotin B and diprotin A (Ile-Pro-Ile) into the active site of hDPPIV. diprotin A 253-264 dipeptidyl peptidase 4 Homo sapiens 112-118 17610364-5 2007 Pretreating purified CD34(+) human CB cells with Diprotin A, a DPPIV inhibitor, for 15 min significantly enhanced engraftment. diprotin A 49-59 CD34 molecule Homo sapiens 21-25 17610364-5 2007 Pretreating purified CD34(+) human CB cells with Diprotin A, a DPPIV inhibitor, for 15 min significantly enhanced engraftment. diprotin A 49-59 dipeptidyl peptidase 4 Homo sapiens 63-68 17610365-4 2007 We report here significant improvements in the engraftment of long-term repopulating cells following the treatment of either CD34(+) or lineage negative (lin()) donor CB with the CD26 inhibitor, Diprotin A, prior to transplant. diprotin A 195-205 CD34 molecule Homo sapiens 125-129 17610365-4 2007 We report here significant improvements in the engraftment of long-term repopulating cells following the treatment of either CD34(+) or lineage negative (lin()) donor CB with the CD26 inhibitor, Diprotin A, prior to transplant. diprotin A 195-205 dipeptidyl peptidase 4 Homo sapiens 179-183 17610366-0 2007 Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. diprotin A 0-10 CD34 molecule Homo sapiens 130-134 17610366-7 2007 Human marrow stromal cells also express CD26, raising the possibility that Diprotin A treatment could significantly enhance engraftment of HSCs in humans in settings of limiting graft dose just as we observed in the NOD/SCID mouse human xenograft model. diprotin A 75-85 dipeptidyl peptidase 4 Homo sapiens 40-44 17280591-12 2007 The NPY-Y5 receptor antagonist resulted in increased GnRH IPI at 15 and 50 days. diprotin A 58-61 neuropeptide Y receptor Y5 Rattus norvegicus 4-19 17280591-12 2007 The NPY-Y5 receptor antagonist resulted in increased GnRH IPI at 15 and 50 days. diprotin A 58-61 gonadotropin releasing hormone 1 Rattus norvegicus 53-57 16406514-8 2006 CONCLUSIONS: Our results suggest that hypermethylation of the p16 promoter indicates a poor prognosis in high-intermediate-risk and high-risk DLBCL patients, and may be a useful marker for selection of appropriate treatment when used in conjunction with the IPI. diprotin A 258-261 cyclin dependent kinase inhibitor 2A Homo sapiens 62-65 16815593-3 2006 An in vitro superfusion system was utilized to investigate the actions of EM1, EM2 and specific DPPIV inhibitor diprotin A on the striatal release of dopamine (DA) induced by electrical stimulation in rats. diprotin A 112-122 dipeptidylpeptidase 4 Rattus norvegicus 96-101 16673127-6 2006 Bcl-2(+)/p53(+) group was found to be associated with advanced stage (p=0.008) and higher IPI (p=0.001), compared with the other groups. diprotin A 90-93 BCL2 apoptosis regulator Homo sapiens 0-5 16673127-6 2006 Bcl-2(+)/p53(+) group was found to be associated with advanced stage (p=0.008) and higher IPI (p=0.001), compared with the other groups. diprotin A 90-93 tumor protein p53 Homo sapiens 9-12 16830142-9 2006 Our results suggest that membrane expression of PKC-beta 2 protein on DLBCL predicts for poor survival, especially in patients with low IPI. diprotin A 136-139 protein kinase C beta Homo sapiens 48-56 17313671-7 2007 Within intermediate- and high-risk IPI groups, elevated PKC-beta expression was associated with worse survival, suggesting that PKC-beta may expand the prognostic value of the IPI. diprotin A 35-38 protein kinase C beta Homo sapiens 56-64 17313671-7 2007 Within intermediate- and high-risk IPI groups, elevated PKC-beta expression was associated with worse survival, suggesting that PKC-beta may expand the prognostic value of the IPI. diprotin A 176-179 protein kinase C beta Homo sapiens 56-64 16341058-5 2006 Expression of the allogeneic MHC class I antigen on bone marrow-derived cells following transplantation of Diprotin A-treated cells was sufficient to induce transplantation tolerance. diprotin A 107-117 H2-T3-like Mus musculus 29-48 16210409-6 2005 Furthermore, SDF-1/CXCL12 induced chemotaxis of ESCs, and chemotaxis could be enhanced by diprotin A inhibition of CD26/dipeptidylpeptidase IV. diprotin A 90-100 chemokine (C-X-C motif) ligand 12 Mus musculus 13-18 16705242-4 2006 The study revealed that the CD10 antigen expression is an unfavorable prognostic factor in the high and high-intermediate risk groups regarding to the IPI, overall survival is shorter in the CD10 positive cases and was 14,1 month compared with 23,5 month in CD10 negative group(p<0,01). diprotin A 151-154 membrane metalloendopeptidase Homo sapiens 191-195 16705242-4 2006 The study revealed that the CD10 antigen expression is an unfavorable prognostic factor in the high and high-intermediate risk groups regarding to the IPI, overall survival is shorter in the CD10 positive cases and was 14,1 month compared with 23,5 month in CD10 negative group(p<0,01). diprotin A 151-154 membrane metalloendopeptidase Homo sapiens 191-195 16690518-6 2006 In the intermediate group risk defined by IPI, patients presenting high level of sIL-2R or IL-6 demonstrated lower CR rate and survival than those with low level. diprotin A 42-45 interleukin 6 Homo sapiens 91-95 16515840-6 2006 The endomorphin-2 but not endomorphin-1 current amplitude was increased by dipeptidyl peptidase IV inhibitor diprotin A (30 microM). diprotin A 109-119 dipeptidylpeptidase 4 Rattus norvegicus 75-98 16705242-4 2006 The study revealed that the CD10 antigen expression is an unfavorable prognostic factor in the high and high-intermediate risk groups regarding to the IPI, overall survival is shorter in the CD10 positive cases and was 14,1 month compared with 23,5 month in CD10 negative group(p<0,01). diprotin A 151-154 membrane metalloendopeptidase Homo sapiens 28-32 16210409-6 2005 Furthermore, SDF-1/CXCL12 induced chemotaxis of ESCs, and chemotaxis could be enhanced by diprotin A inhibition of CD26/dipeptidylpeptidase IV. diprotin A 90-100 chemokine (C-X-C motif) ligand 12 Mus musculus 19-25 16210409-6 2005 Furthermore, SDF-1/CXCL12 induced chemotaxis of ESCs, and chemotaxis could be enhanced by diprotin A inhibition of CD26/dipeptidylpeptidase IV. diprotin A 90-100 dipeptidylpeptidase 4 Mus musculus 115-119 16210409-6 2005 Furthermore, SDF-1/CXCL12 induced chemotaxis of ESCs, and chemotaxis could be enhanced by diprotin A inhibition of CD26/dipeptidylpeptidase IV. diprotin A 90-100 dipeptidylpeptidase 4 Mus musculus 120-142 15183349-7 2004 When combined in HIV-1-infected cell cultures, IlePyr and Diprotin A (DP-A), another CD26/DPP IV inhibitor, abrogated the antiviral activity of GPG-NH2 but not of G-NH2. diprotin A 58-68 dipeptidyl peptidase 4 Homo sapiens 85-89 15720419-8 2005 Among patients in the low-risk IPI group, CD10 positivity was associated with an excellent 8-year overall survival (92% versus 45%, P = 0.06). diprotin A 31-34 membrane metalloendopeptidase Homo sapiens 42-46 15720419-9 2005 In the high-risk IPI group, Bcl-2 positivity identified a subgroup with invariably fatal disease. diprotin A 17-20 BCL2 apoptosis regulator Homo sapiens 28-33 15621801-8 2005 On multivariate analysis for overall survival in patients with CD20-positive PTLD, low IPI (P = 0.004) and rituximab therapy (P = 0.03) were significant. diprotin A 87-90 keratin 20 Homo sapiens 63-67 15621801-9 2005 Low IPI and rituximab therapy led to an improved overall survival in patients with CD20-positive PTLD. diprotin A 4-7 keratin 20 Homo sapiens 83-87 15370252-15 2004 Therefore, the association of IPI with cellular factors, such as p53 mutation, can be very helpful in deciding when we should indicate more aggressive therapies in patients with DLBCL, to somehow increase the chance of cure in these patients. diprotin A 30-33 tumor protein p53 Homo sapiens 65-68 16050949-4 2005 In this study, we determined cell growth, insulin content, insulin accumulation and insulin secretory function of a insulin-secreting cell line cultured for 3 days with either GLP-1, GLP-1 plus the DPP IV inhibitor diprotin A (DPA) or stable N-acetyl-GLP-1. diprotin A 215-225 dipeptidyl peptidase 4 Homo sapiens 198-204 15183349-7 2004 When combined in HIV-1-infected cell cultures, IlePyr and Diprotin A (DP-A), another CD26/DPP IV inhibitor, abrogated the antiviral activity of GPG-NH2 but not of G-NH2. diprotin A 58-68 dipeptidyl peptidase 4 Homo sapiens 90-96 15183349-7 2004 When combined in HIV-1-infected cell cultures, IlePyr and Diprotin A (DP-A), another CD26/DPP IV inhibitor, abrogated the antiviral activity of GPG-NH2 but not of G-NH2. diprotin A 70-74 dipeptidyl peptidase 4 Homo sapiens 85-89 15183349-7 2004 When combined in HIV-1-infected cell cultures, IlePyr and Diprotin A (DP-A), another CD26/DPP IV inhibitor, abrogated the antiviral activity of GPG-NH2 but not of G-NH2. diprotin A 70-74 dipeptidyl peptidase 4 Homo sapiens 90-96 12904562-7 2003 It was inhibited by serine protease inhibitors and the substrate analogue for mammalian DPP-IV, diprotin A. diprotin A 96-106 dipeptidyl peptidase 4 Homo sapiens 88-94 15255191-0 2004 The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A. diprotin A 76-86 dipeptidyl peptidase 4 Homo sapiens 31-54 15255191-0 2004 The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A. diprotin A 76-86 dipeptidyl peptidase 4 Homo sapiens 56-61 15255191-3 2004 In order to elucidate the binding mode and substrate specificity, we determined the crystal structure complex of hDPPIV and diprotin A (IIe-Pro-IIe), a slowly hydrolyzed substrate of hDPPIV, at 2.2 A resolution. diprotin A 124-134 dipeptidyl peptidase 4 Homo sapiens 113-119 15255191-3 2004 In order to elucidate the binding mode and substrate specificity, we determined the crystal structure complex of hDPPIV and diprotin A (IIe-Pro-IIe), a slowly hydrolyzed substrate of hDPPIV, at 2.2 A resolution. diprotin A 124-134 dipeptidyl peptidase 4 Homo sapiens 183-189 14679917-8 2003 CONCLUSIONS: The IPI is confirmed as an important tool for prognostic evaluation of NHL patients: an integration of IPI, histological grading and serum beta 2-microglobulin concentration is supported. diprotin A 17-20 beta-2-microglobulin Homo sapiens 152-172 12749011-10 2003 However, bcl-2 expression was found to be unfavorably associated with the OS (P = 0.0054) in a confined group with low (n = 51) or low intermediate (n = 22) IPI scores. diprotin A 157-160 BCL2 apoptosis regulator Homo sapiens 9-14 12478000-6 2002 There was a correlation between the patients with high risk according to the IPI criteria and high levels of serum cytokines (IL-2, IL-6, IL-10). diprotin A 77-80 interleukin 2 Homo sapiens 126-130 12478000-6 2002 There was a correlation between the patients with high risk according to the IPI criteria and high levels of serum cytokines (IL-2, IL-6, IL-10). diprotin A 77-80 interleukin 6 Homo sapiens 132-136 12478000-6 2002 There was a correlation between the patients with high risk according to the IPI criteria and high levels of serum cytokines (IL-2, IL-6, IL-10). diprotin A 77-80 interleukin 10 Homo sapiens 138-143 11241273-10 2001 Diprotin A, an inhibitor of dipeptidyl peptidase IV, was without effect. diprotin A 0-10 dipeptidyl peptidase 4 Homo sapiens 28-51 12213886-7 2002 When a competitive inhibitor of DPPIV, diprotin A, was added in Matrigel invasion assay system, JEG-3 cells exhibited a significant enhancement of invasion. diprotin A 39-49 dipeptidyl peptidase 4 Homo sapiens 32-37 11337057-6 2001 Diprotin-A, a potent inhibitor of dipeptidyl peptidase IV, provided significant inhibition of the degradation of ENI in the presence of buccal epithelium. diprotin A 0-10 dipeptidyl peptidase 4 Homo sapiens 34-57 11830458-7 2002 Expression of bcl-2 in the intermediate IPI group identified a further 28% of patients with an overall survival comparable to the high IPI group. diprotin A 40-43 BCL2 apoptosis regulator Homo sapiens 14-19 11830458-7 2002 Expression of bcl-2 in the intermediate IPI group identified a further 28% of patients with an overall survival comparable to the high IPI group. diprotin A 135-138 BCL2 apoptosis regulator Homo sapiens 14-19 11830458-8 2002 In the intermediate IPI, bcl-2(-) group, the presence of a GC phenotype improved overall survival to levels approaching the IPI low group. diprotin A 124-127 BCL2 apoptosis regulator Homo sapiens 25-30 10569731-7 1999 Among various inhibitors tested, diprotin A and phenylmethylsulfonyl fluoride inhibited the enzymatic activity, suggesting that the enzyme induced by IL-1alpha was DPPIV. diprotin A 33-43 interleukin 1 alpha Homo sapiens 150-159 11793435-3 2001 Both IPI tests are based on the fact that HLA-antibodies specifically bind to antigens on the monocyte surface via their Fab portion, and in so doing block a neighbouring FcgammaR with their Fc region. diprotin A 5-8 FA complementation group B Homo sapiens 121-124 10654583-3 2000 The antidromic population spike (PS1) presented paired-pulse facilitation at low-IPI, which decayed exponentially at increasing IPI. diprotin A 81-84 presenilin 1 Rattus norvegicus 33-36 10654583-3 2000 The antidromic population spike (PS1) presented paired-pulse facilitation at low-IPI, which decayed exponentially at increasing IPI. diprotin A 128-131 presenilin 1 Rattus norvegicus 33-36 10654583-5 2000 BMI reduced, but GBZ enhanced the low-IPI paired-pulse inhibition of the orthodromic PS2. diprotin A 38-41 trefoil factor 1 Rattus norvegicus 85-88 11172955-19 2001 There was a clear trend for increasing PCR positivity with increasing IPI: 10% for IPI = 0, 31% for IPI = 1, and 63% for IPI = 2 at 3 years for blood. diprotin A 70-73 testis expressed 10 Homo sapiens 100-107 11111014-7 2001 The formation of GLP-1(9-36)amide from native tGLP-1 was almost totally abolished by addition of diprotin A, a specific inhibitor of DPP IV. diprotin A 97-107 glucagon Mus musculus 17-22 11111014-7 2001 The formation of GLP-1(9-36)amide from native tGLP-1 was almost totally abolished by addition of diprotin A, a specific inhibitor of DPP IV. diprotin A 97-107 dipeptidylpeptidase 4 Mus musculus 133-139 10828847-5 2000 The formation of GIP(3-42) was almost completely abolished by inhibition of plasma DPP IV with diprotin A. diprotin A 95-105 gastric inhibitory polypeptide Mus musculus 17-20 10828847-5 2000 The formation of GIP(3-42) was almost completely abolished by inhibition of plasma DPP IV with diprotin A. diprotin A 95-105 dipeptidylpeptidase 4 Mus musculus 83-89 10773218-8 2000 CGP35348 increased PS1 mainly by blocking tonic postsynaptic GABA(B) receptors and decreased PS2 at 30-70 ms IPI by blocking presynaptic GABA(B) autoreceptors. diprotin A 109-112 trefoil factor 1 Rattus norvegicus 93-96 10569731-7 1999 Among various inhibitors tested, diprotin A and phenylmethylsulfonyl fluoride inhibited the enzymatic activity, suggesting that the enzyme induced by IL-1alpha was DPPIV. diprotin A 33-43 dipeptidyl peptidase 4 Homo sapiens 164-169 10102692-7 1999 The formation of GIP(3-42) was almost completely abolished by inhibition of plasma DPP IV with diprotin A. diprotin A 95-105 gastric inhibitory polypeptide Homo sapiens 17-20 10102692-7 1999 The formation of GIP(3-42) was almost completely abolished by inhibition of plasma DPP IV with diprotin A. diprotin A 95-105 dipeptidyl peptidase 4 Homo sapiens 83-89 9053471-9 1997 The addition of the TNF ligand-receptor-based model to the International Prognostic Index (IPI) yielded a significant improvement of the predictive value of IPI. diprotin A 91-94 tumor necrosis factor Homo sapiens 20-23 9809800-8 1998 The difference in metabolism persisted after addition of diprotin A, an inhibitor of dipeptidyl peptidase IV, the enzyme responsible for the initial degradation of GLP-1 in plasma, and broader enzyme inhibitors. diprotin A 57-67 dipeptidyl peptidase 4 Homo sapiens 85-108 9809800-8 1998 The difference in metabolism persisted after addition of diprotin A, an inhibitor of dipeptidyl peptidase IV, the enzyme responsible for the initial degradation of GLP-1 in plasma, and broader enzyme inhibitors. diprotin A 57-67 glucagon Homo sapiens 164-169 9401784-7 1997 Kininases were identified by ramiprilat, phosphoramidon, diprotin A and 2-mercaptoethanol or apstatin as specific inhibitors of ACE, neutral endopeptidase 24.11 (NEP), dipeptidylaminopeptidase IV and aminopeptidase P (APP), respectively. diprotin A 57-67 angiotensin I converting enzyme Rattus norvegicus 128-131 8594513-8 1996 When compared with the natural course in a very similar group of patients previously reported, tPA had a statistically significant beneficial effect in the maintenance of IPI patency (P = 0.040). diprotin A 171-174 chromosome 20 open reading frame 181 Homo sapiens 95-98 8833407-5 1996 The best correlation was obtained between the values of r-TNF-alpha and r-beta-2-m and IPI, however r-TNF-alpha best stratify the four risk groups in this prognosis index. diprotin A 87-90 beta-2-microglobulin Homo sapiens 74-82 9266284-5 1997 However, in the presence of dipeptidylpeptidase IV/CD26 and neutral endopeptidase/CD10 inhibitors (diprotin A and thiorphan, respectively), the effect of substance P on mitogen-induced proliferation was significantly increased. diprotin A 99-109 dipeptidyl peptidase 4 Homo sapiens 28-50 9266284-5 1997 However, in the presence of dipeptidylpeptidase IV/CD26 and neutral endopeptidase/CD10 inhibitors (diprotin A and thiorphan, respectively), the effect of substance P on mitogen-induced proliferation was significantly increased. diprotin A 99-109 tachykinin precursor 1 Homo sapiens 154-165 8938667-3 1996 This latter effect was increased in rat paws by captopril, an inhibitor of angiotensin-converting enzyme (ACE), administered locally in combination with diprotin A, an inhibitor of an dipeptidyl(amino)peptidase IV (DAP IV) or phosphoramidon, an inhibitor of neutral endopeptidase (NEP). diprotin A 153-163 membrane metallo-endopeptidase Rattus norvegicus 258-279 8938667-3 1996 This latter effect was increased in rat paws by captopril, an inhibitor of angiotensin-converting enzyme (ACE), administered locally in combination with diprotin A, an inhibitor of an dipeptidyl(amino)peptidase IV (DAP IV) or phosphoramidon, an inhibitor of neutral endopeptidase (NEP). diprotin A 153-163 membrane metallo-endopeptidase Rattus norvegicus 281-284 8683246-8 1996 Bcl2 was the strongest independent prognostic value in a multivariate analysis, with a relative risk (RR) of 3.0 in comparison to p53 expression and the clinical factors of the IPI. diprotin A 177-180 BCL2 apoptosis regulator Homo sapiens 0-4 8594513-9 1996 CONCLUSIONS: Intraocular tPA can be safely used to lyse postoperative fibrin occluding the IPI in eyes with silicone oil tamponade. diprotin A 91-94 chromosome 20 open reading frame 181 Homo sapiens 25-28 8951616-2 1996 Serum DPPIV, a serine enzyme with an apparent mass of 250 kDa, consists of two identical subunits with an apparent mass of 100 kDa and is inhibited by DPPIV-specific inhibitor Diprotin A and also by p-chloromercuribenzoate (p-CMB), 2-mercaptoethanol, HgCl2, CdCl2, SrCl2, and ZnCl2. diprotin A 176-186 dipeptidyl peptidase 4 Homo sapiens 6-11 8951616-2 1996 Serum DPPIV, a serine enzyme with an apparent mass of 250 kDa, consists of two identical subunits with an apparent mass of 100 kDa and is inhibited by DPPIV-specific inhibitor Diprotin A and also by p-chloromercuribenzoate (p-CMB), 2-mercaptoethanol, HgCl2, CdCl2, SrCl2, and ZnCl2. diprotin A 176-186 dipeptidyl peptidase 4 Homo sapiens 151-156 7714663-11 1995 Among the protease inhibitors, only two, diprotin-A and phenylmethylsulfonyl fluoride (PMSA), could inhibit DPPIV activity. diprotin A 41-51 dipeptidyl peptidase 4 Homo sapiens 108-113 7628397-8 1995 These products were significantly reduced when the specific DPP IV inhibitor diprotin A was included in the incubation mixture and were absent when serum from DPP IV-deficient rats was used. diprotin A 77-87 dipeptidylpeptidase 4 Rattus norvegicus 60-66 35614936-5 2022 Results: IPI was constructed based on the expression of 5 genes, including A2M, ADRB1, ADRB2, VIPR1 and PTH1R. diprotin A 9-12 alpha-2-macroglobulin Homo sapiens 75-78 1363432-9 1992 Diprotin A also allowed the recovery of BK2-9. diprotin A 0-10 potassium voltage-gated channel subfamily A member 2 Rattus norvegicus 40-45 1671823-4 1991 Antibiotics 37, 422-425) reported that diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) are inhibitors for dipeptidyl peptidase IV. diprotin A 39-49 dipeptidyl peptidase 4 Homo sapiens 112-135 1671823-4 1991 Antibiotics 37, 422-425) reported that diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) are inhibitors for dipeptidyl peptidase IV. diprotin A 51-62 dipeptidyl peptidase 4 Homo sapiens 112-135 1700400-7 1990 The rank order of potency of the peptidase inhibitors in decreasing the magnitude of SP-induced desensitization was BAC = PH much greater than ACEI greater than DPA. diprotin A 161-164 tachykinin 1 Mus musculus 85-87 34745101-7 2021 The comprehensive results showed that high IPI-IPM risk scores were correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, and upregulation of inhibitory immune checkpoints, including PD-L1, BTLA, and SIGLEC7, indicating a greater potential response to ICB therapy. diprotin A 43-46 lysine methyltransferase 2D Homo sapiens 124-129 34745101-7 2021 The comprehensive results showed that high IPI-IPM risk scores were correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, and upregulation of inhibitory immune checkpoints, including PD-L1, BTLA, and SIGLEC7, indicating a greater potential response to ICB therapy. diprotin A 43-46 CD79b molecule Homo sapiens 134-139 34745101-7 2021 The comprehensive results showed that high IPI-IPM risk scores were correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, and upregulation of inhibitory immune checkpoints, including PD-L1, BTLA, and SIGLEC7, indicating a greater potential response to ICB therapy. diprotin A 43-46 CD274 molecule Homo sapiens 217-222 34745101-7 2021 The comprehensive results showed that high IPI-IPM risk scores were correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, and upregulation of inhibitory immune checkpoints, including PD-L1, BTLA, and SIGLEC7, indicating a greater potential response to ICB therapy. diprotin A 43-46 B and T lymphocyte associated Homo sapiens 224-228 34745101-7 2021 The comprehensive results showed that high IPI-IPM risk scores were correlated with immune-related signaling pathways, high KMT2D and CD79B mutation rates, and upregulation of inhibitory immune checkpoints, including PD-L1, BTLA, and SIGLEC7, indicating a greater potential response to ICB therapy. diprotin A 43-46 sialic acid binding Ig like lectin 7 Homo sapiens 234-241 34181278-4 2021 The IPI was calculated as neutrophil-to-lymphocyte ratio (NLR) x C-reactive protein to albumin ratio (CAR). diprotin A 4-7 C-reactive protein Homo sapiens 65-83 34181278-4 2021 The IPI was calculated as neutrophil-to-lymphocyte ratio (NLR) x C-reactive protein to albumin ratio (CAR). diprotin A 4-7 albumin Homo sapiens 87-94 34181278-4 2021 The IPI was calculated as neutrophil-to-lymphocyte ratio (NLR) x C-reactive protein to albumin ratio (CAR). diprotin A 4-7 CXADR pseudogene 1 Homo sapiens 102-105 35615279-1 2022 Background: It has been established that the dipeptidyl peptidase-4 (DPP-4) inhibitor Diprotin A TFA can reduce vascular endothelial (VE)-cadherin disruption by inhibiting the increase in cleaved beta-catenin in response to hypoxia, thereby protecting the vascular barrier of human umbilical vein endothelial cells. diprotin A 86-96 cadherin 5 Homo sapiens 112-146 35615279-1 2022 Background: It has been established that the dipeptidyl peptidase-4 (DPP-4) inhibitor Diprotin A TFA can reduce vascular endothelial (VE)-cadherin disruption by inhibiting the increase in cleaved beta-catenin in response to hypoxia, thereby protecting the vascular barrier of human umbilical vein endothelial cells. diprotin A 86-96 catenin beta 1 Homo sapiens 196-208 7907802-5 1993 Formation of Tyr-Pro in serum was blocked in the presence of Lys-pyrrolidine and diprotin A (Ile-Pro-Ile), specific, competitive inhibitors of dipeptidyl peptidase IV. diprotin A 81-91 dipeptidyl peptidase 4 Homo sapiens 143-166 7907802-5 1993 Formation of Tyr-Pro in serum was blocked in the presence of Lys-pyrrolidine and diprotin A (Ile-Pro-Ile), specific, competitive inhibitors of dipeptidyl peptidase IV. diprotin A 93-104 dipeptidyl peptidase 4 Homo sapiens 143-166 1572909-2 1992 One activity removing dipeptides from the NH2-terminal end of Gly-Pro-pNA was specifically inhibited by di-isopropyl-fluorophosphate (DFP), phenylmethanesulphony fluoride (PMSF), and diprotin A, and thus was identified as dipeptidyl peptidase IV (DPP IV). diprotin A 183-193 dipeptidyl peptidase 4 Homo sapiens 222-245 1572909-2 1992 One activity removing dipeptides from the NH2-terminal end of Gly-Pro-pNA was specifically inhibited by di-isopropyl-fluorophosphate (DFP), phenylmethanesulphony fluoride (PMSF), and diprotin A, and thus was identified as dipeptidyl peptidase IV (DPP IV). diprotin A 183-193 dipeptidyl peptidase 4 Homo sapiens 247-253 1844619-2 1991 The IPI was calculated using the following formula: [formula: see text] 13.2 (DFO) + 22 (DAT) + 8.9 (DAP) - 48.4 (LF) - 7469.1, and ETF = 0.55 (LF) + 8.66. diprotin A 4-7 solute carrier family 6 member 3 Homo sapiens 89-92 1844619-2 1991 The IPI was calculated using the following formula: [formula: see text] 13.2 (DFO) + 22 (DAT) + 8.9 (DAP) - 48.4 (LF) - 7469.1, and ETF = 0.55 (LF) + 8.66. diprotin A 4-7 death associated protein Homo sapiens 101-104 33782030-7 2021 Multiple inflammatory gene signatures/transcripts, including a signature consisting of 4 genes (CD274, CD8A, LAG3, and STAT1), showed associations with response to NIVO{plus minus}IPI. diprotin A 180-183 CD274 molecule Homo sapiens 96-101 33782030-7 2021 Multiple inflammatory gene signatures/transcripts, including a signature consisting of 4 genes (CD274, CD8A, LAG3, and STAT1), showed associations with response to NIVO{plus minus}IPI. diprotin A 180-183 CD8a molecule Homo sapiens 103-107 33782030-7 2021 Multiple inflammatory gene signatures/transcripts, including a signature consisting of 4 genes (CD274, CD8A, LAG3, and STAT1), showed associations with response to NIVO{plus minus}IPI. diprotin A 180-183 lymphocyte activating 3 Homo sapiens 109-113 33782030-7 2021 Multiple inflammatory gene signatures/transcripts, including a signature consisting of 4 genes (CD274, CD8A, LAG3, and STAT1), showed associations with response to NIVO{plus minus}IPI. diprotin A 180-183 signal transducer and activator of transcription 1 Homo sapiens 119-124 33782030-8 2021 CONCLUSIONS: This study suggests a greater association of PD-L1 expression by CPS with NIVO{plus minus}IPI efficacy compared with %TC PD-L1 expression in patients with GC/GEJC. diprotin A 103-106 CD274 molecule Homo sapiens 58-63 34915642-8 2021 After IPI correction by Cox multivariate model, the elevated C1QA signal value was still correlated with poor PFS (HR=1.765, 95%CI 1.034~3.013, P=0.037). diprotin A 6-9 complement C1q A chain Homo sapiens 61-65 34868146-13 2021 The overexpression of IPI in a F1 cross showed a significant increase in EGF expression. diprotin A 22-25 epidermal growth factor Homo sapiens 73-76 34405230-6 2021 COPD macrophages also showed higher expression of IL-1beta, and CCL3 responses to NTHi than normal, and treatment with DPP4 inhibitor, diprotin A attenuated this response. diprotin A 135-145 interleukin 1 alpha Mus musculus 50-58 34405230-6 2021 COPD macrophages also showed higher expression of IL-1beta, and CCL3 responses to NTHi than normal, and treatment with DPP4 inhibitor, diprotin A attenuated this response. diprotin A 135-145 C-C motif chemokine ligand 3 Homo sapiens 64-68 34405230-6 2021 COPD macrophages also showed higher expression of IL-1beta, and CCL3 responses to NTHi than normal, and treatment with DPP4 inhibitor, diprotin A attenuated this response. diprotin A 135-145 dipeptidyl peptidase 4 Homo sapiens 119-123 35615279-1 2022 Background: It has been established that the dipeptidyl peptidase-4 (DPP-4) inhibitor Diprotin A TFA can reduce vascular endothelial (VE)-cadherin disruption by inhibiting the increase in cleaved beta-catenin in response to hypoxia, thereby protecting the vascular barrier of human umbilical vein endothelial cells. diprotin A 86-96 dipeptidyl peptidase 4 Homo sapiens 45-67 35615279-1 2022 Background: It has been established that the dipeptidyl peptidase-4 (DPP-4) inhibitor Diprotin A TFA can reduce vascular endothelial (VE)-cadherin disruption by inhibiting the increase in cleaved beta-catenin in response to hypoxia, thereby protecting the vascular barrier of human umbilical vein endothelial cells. diprotin A 86-96 dipeptidyl peptidase 4 Homo sapiens 69-74 35614936-5 2022 Results: IPI was constructed based on the expression of 5 genes, including A2M, ADRB1, ADRB2, VIPR1 and PTH1R. diprotin A 9-12 adrenoceptor beta 1 Homo sapiens 80-85 35614936-5 2022 Results: IPI was constructed based on the expression of 5 genes, including A2M, ADRB1, ADRB2, VIPR1 and PTH1R. diprotin A 9-12 adrenoceptor beta 2 Homo sapiens 87-92 35614936-5 2022 Results: IPI was constructed based on the expression of 5 genes, including A2M, ADRB1, ADRB2, VIPR1 and PTH1R. diprotin A 9-12 vasoactive intestinal peptide receptor 1 Homo sapiens 94-99 35614936-5 2022 Results: IPI was constructed based on the expression of 5 genes, including A2M, ADRB1, ADRB2, VIPR1 and PTH1R. diprotin A 9-12 parathyroid hormone 1 receptor Homo sapiens 104-109 35614936-7 2022 The comprehensive results showed that patients in the IPI-high subgroup were exhibited characters as metabolism-related signaling pathways activation, lower TP53 and TTN mutation rate, more infiltrations of CD8 T cells, dendritic cells and macrophages M1, especially earned more benefit from ICB treatment. diprotin A 54-57 tumor protein p53 Homo sapiens 157-161 35614936-7 2022 The comprehensive results showed that patients in the IPI-high subgroup were exhibited characters as metabolism-related signaling pathways activation, lower TP53 and TTN mutation rate, more infiltrations of CD8 T cells, dendritic cells and macrophages M1, especially earned more benefit from ICB treatment. diprotin A 54-57 titin Homo sapiens 166-169 35614936-7 2022 The comprehensive results showed that patients in the IPI-high subgroup were exhibited characters as metabolism-related signaling pathways activation, lower TP53 and TTN mutation rate, more infiltrations of CD8 T cells, dendritic cells and macrophages M1, especially earned more benefit from ICB treatment. diprotin A 54-57 CD8a molecule Homo sapiens 207-210 35574252-4 2022 IC50 value of resveratrol and taxifolin (5.638 +- .0016 mu M and 6.691 +- .004 mu M ) in comparison to diprotin A (IC50: 7.21 +- .021 mu M ) showed that they have significant inhibitory effect on DPP-IV enzyme. diprotin A 105-115 dipeptidyl peptidase 4 Homo sapiens 199-205 35614936-8 2022 In contrast, patients in the IPI-low subgroup were exhibited characters as p53 signaling pathways activation, higher TP53 and TTN mutation rate, more infiltrations of resting memory CD4 T cells, macrophages M2, immune-suppressive response and less benefit from ICB treatment. diprotin A 29-32 tumor protein p53 Homo sapiens 75-78 35614936-8 2022 In contrast, patients in the IPI-low subgroup were exhibited characters as p53 signaling pathways activation, higher TP53 and TTN mutation rate, more infiltrations of resting memory CD4 T cells, macrophages M2, immune-suppressive response and less benefit from ICB treatment. diprotin A 29-32 tumor protein p53 Homo sapiens 117-121 35614936-8 2022 In contrast, patients in the IPI-low subgroup were exhibited characters as p53 signaling pathways activation, higher TP53 and TTN mutation rate, more infiltrations of resting memory CD4 T cells, macrophages M2, immune-suppressive response and less benefit from ICB treatment. diprotin A 29-32 titin Homo sapiens 126-129 35614936-8 2022 In contrast, patients in the IPI-low subgroup were exhibited characters as p53 signaling pathways activation, higher TP53 and TTN mutation rate, more infiltrations of resting memory CD4 T cells, macrophages M2, immune-suppressive response and less benefit from ICB treatment. diprotin A 29-32 CD4 molecule Homo sapiens 182-185